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Abstract
The effectiveness and cost-effectiveness of acupressure 
for the control and management of chemotherapy-
related acute and delayed nausea: Assessment of Nausea 
in Chemotherapy Research (ANCHoR), a randomised 
controlled trial
A Molassiotis,1,2* W Russell,1 J Hughes,3 M Breckons,4 
M Lloyd-Williams,3 J Richardson,4 C Hulme,5 S Brearley,6 
M Campbell,1 A Garrow7 and WD Ryder8
1School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK
2School of Nursing, The Hong Kong Polytechnic University, Hong Kong
3Academic Palliative and Supportive Care Studies Group, Division of Primary Care, University of 
Liverpool, Liverpool, UK
4Faculty of Health, Education and Society, University of Plymouth, Plymouth, UK
5Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, 
Leeds, UK
6Faculty of Health and Medicine, Lancaster University, Lancaster, UK
7School of Health Sciences, University of Salford, Manchester, UK
8Clinical Trials Unit, Christie NHS Foundation Trust, Manchester, UK
*Corresponding author alex.molassiotis@manchester.ac.uk
Background: Chemotherapy-induced nausea and vomiting remain difficult symptoms to manage in 
clinical practice. As standard antiemetic drugs do not fully eliminate these symptoms, it is important to 
explore the adjuvant role of non-pharmacological and complementary therapies in antiemetic 
management approaches. Acupressure is one such treatment showing highly suggestive evidence so far of 
a positive effect, meriting further investigation.
Objectives: The primary objective was to assess the effectiveness and cost-effectiveness of self-
acupressure using wristbands compared with sham acupressure wristbands and standard care alone in the 
management of chemotherapy-induced nausea. Secondary objectives included assessment of the 
effectiveness and cost-effectiveness of the wristbands in relation to vomiting and quality of life and 
exploration of any age, gender and emetogenic risk effects.
Design: Randomised three-arm sham-controlled trial (Assessment of Nausea in Chemotherapy Research 
or ANCHoR) with an economic evaluation. Arms include the wristband arm, the sham wristband arm and 
the standard care only arm. Randomisation consisted of minimisation with a random element balancing 
for gender, age (16–24, > 24–50, >50 years) and three levels of emetogenic chemotherapy (low, 
moderate and high). Qualitative interviews were incorporated to shed more light on the 
quantitative findings. 
Setting: Outpatient chemotherapy clinics in three regions in the UK involving 14 different cancer 
units/centres.
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Participants: Chemotherapy-naive cancer patients receiving chemotherapy of low, moderate and high 
emetogenic risk.
Intervention: The intervention was acupressure wristbands pressing the P6 point (anterior surface of 
the forearm).
Main outcome measures: The Rhodes Index for Nausea/Vomiting, the Multinational Association of 
Supportive Care in Cancer (MASCC) Antiemesis Tool and the Functional Assessment of Cancer Therapy – 
General (FACT-G). At baseline participants completed measures of anxiety/depression, nausea/vomiting 
expectation and expectations from using the wristbands.
Results: In total, 500 patients were randomised in the study arms (166 standard care, 166 sham 
acupressure and 168 acupressure) and data were available for 361 participants for the primary outcome. 
The primary outcome analysis (nausea in cycle 1) revealed no statistically significant differences between 
the three arms, although the median nausea experience in patients using wristbands (both real and sham 
ones) was somewhat lower than that in the antiemetics only group (median nausea experience scores for 
the four cycles: standard care arm 1.43, 1.71, 1.14, 1.14; sham acupressure arm 0.57, 0.71, 0.71, 0.43; 
acupressure arm 1.00, 0.93, 0.43, 0). A gender effect was evident (p = 0.002), with women responding 
more favourably to the use of sham acupressure wristbands than men (odds ratio 0.35 for men and 2.02 
for women in the sham acupressure group; 1.27 for men and 1.17 for women in the acupressure group). 
This suggests a placebo effect. No significant differences were detected in relation to vomiting outcomes, 
anxiety and quality of life. Some transient adverse effects were reported, including tightness in the area of 
the wristbands, feeling uncomfortable when wearing them and minor swelling in the wristband area 
(n = 6).There were no statistically significant cost differences associated with the use of real acupressure 
bands (£70.66 for the acupressure group, £111.13 for the standard care group and £161.92 for the sham 
acupressure group). In total, 26 subjects took part in qualitative interviews. The qualitative data suggested 
that participants perceived the wristbands (both real and sham) as effective and helpful in managing their 
nausea during chemotherapy.
Conclusions: There were no statistically significant differences between the three arms in terms of 
nausea, vomiting and quality of life, although apparent resource use was less in both the real acupressure 
arm and the sham acupressure arm compared with standard care only; therefore; no clear conclusions can 
be drawn about the use of acupressure wristbands in the management of chemotherapy-related nausea 
and vomiting. However, the study provided encouraging evidence in relation to an improved nausea 
experience and some indications of possible cost savings to warrant further consideration of acupressure 
both in practice and in further clinical trials.
Trial registration: ISRCTN87604299.
Source of funding: This project was funded by the NIHR Health Technology Assessment programme and 
will be published in full in Health Technology Assessment; Vol. 17, No. 26. See the HTA programme 
website for further project information.
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Scientific summary
Background
Although chemotherapy-related vomiting is relatively well controlled with current antiemetics, nausea 
remains a significant problem for patients and a difficult symptom for clinicians to manage. The role of 
complementary therapies, and particularly acupressure at the P6 (Neiguan) point, as adjunctive treatments 
to pharmacological antiemetics has been investigated in a number of studies in the past. Both positive 
and negative results have been reported in the literature, providing highly suggestive but not conclusive 
evidence. Many past studies, however, are hampered by methodological problems, including small sample 
sizes, minimal control of risk factors for chemotherapy-related nausea and vomiting and no control of the 
antiemetic drugs used. Hence, there is a need to clarify whether or not acupressure is effective and cost-
effective in the management of chemotherapy-related nausea and vomiting using a robust methodological 
design with a well-powered sample size.
Objectives
Primary objective
1. To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care 
compared with standard care with sham acupressure wristbands and standard care alone in the 
management of chemotherapy-induced (acute and delayed) nausea.
Secondary objectives
2. To assess the cost-effectiveness and extent of use of usual care in patients using acupressure 
wristbands in addition to standard care compared with that in patients undergoing standard 
care with sham acupressure wristbands and standard care alone for the management of 
chemotherapy-induced nausea.
3. To assess the quality of life of patients using acupressure wristbands in addition to standard care 
compared with that of patients receiving standard care with sham acupressure wristbands and 
standard care alone in the management of chemotherapy-induced nausea and vomiting.
4. To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care 
compared with that of standard care with sham acupressure wristbands and standard care alone in 
the management of chemotherapy-induced (acute and delayed) vomiting.
5. To ascertain for which emetogenic level of chemotherapy regimen (i.e. high, moderate or low) self-
acupressure using wristbands in addition to standard care is more or less effective in terms of nausea 
compared with standard care with sham acupressure wristbands and standard care alone.
6. To ascertain whether or not any improvement in chemotherapy-induced nausea and vomiting from 
using acupressure wristbands is different between men and women.
7. To ascertain whether or not there is an age effect from the use of acupressure wristbands in relation to 
chemotherapy-induced nausea and vomiting.
Methods
A randomised three-group sham-controlled trial (Assessment of Nausea in Chemotherapy Research or 
ANCHoR) was designed to test the effects of acupressure in the management of chemotherapy-related 
nausea and vomiting. Patients with heterogeneous cancer diagnoses receiving chemotherapy of low, 
moderate and high emetogenic potential were randomised to receive acupressure wristbands in addition 
to standardised antiemetics, sham acupressure wristbands in addition to standardised antiemetics or 
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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antiemetics alone. The randomisation method used consisted of minimisation with a random element 
(stochastic minimisation), balancing for gender, age (16–24, > 24–50, > 50 years) and three levels of 
emetogenic chemotherapy [low, moderate and high according to international American Society of Clinical 
Oncology (ASCO) and Multinational Association of Supportive Care in Cancer (MASCC) classifications]. 
Patients were instructed to wear the wristbands throughout the day for the first 7 days during each cycle 
of chemotherapy. The primary outcome assessment using the Rhodes Index of Nausea, Vomiting and 
Retching was carried out daily for 7 days per chemotherapy cycle over four cycles. Other assessments, 
completed at day 6 of each of the four cycles, included the MASCC Antiemesis Tool, the European Quality 
of Life-5 Dimensions (EQ-5D) utility scale and the Functional Assessment of Cancer Therapy – General 
(FACT-G) quality-of-life scale. At baseline participants completed measures of anxiety and depression, 
nausea/vomiting expectation and expectations from using the acupressure wristbands. An economic 
evaluation was also carried out based on drug and health service utilisation from the perspective of the 
health and social care provider and presenting incremental cost-effectiveness ratios with quality-adjusted 
life-years as the outcome. Finally, a nested qualitative interview study was incorporated to shed more light 
on the quantitative findings.
Results
In total, 500 patients were randomised in the study arms (166 standard care, 166 sham acupressure and 
168 acupressure) and data were available for 361 participants for the primary outcome. The primary 
outcome analysis (nausea in cycle 1) revealed no statistically significant differences between the three 
groups, although nausea level in the patients using wristbands (both real and sham) was somewhat lower 
than that in the antiemetics only group (median nausea experience scores for the four cycles: standard 
care arm 1.43, 1.71, 1.14, 1.14; sham acupressure arm 0.57, 0.71, 0.71, 0.43; acupressure arm 1.00, 
0.93, 0.43, 0). Adjusting for gender, age and emetic risk of the chemotherapy, the odds ratio (OR) of a 
lower nausea experience was 1.18 for the acupressure group and 1.42 for the sham acupressure group. 
A gender interaction effect was evident in the data (p = 0.002), with women responding more favourably 
to the use of sham acupressure wristbands than men (OR 0.35 for men and 2.02 for women in the sham 
group; 1.27 for men and 1.17 for women in the real acupressure group). This suggests a placebo effect. 
No significant differences were detected in relation to vomiting outcomes, anxiety and quality of life. The 
cost-effectiveness evaluation revealed no significant differences (t-tests) between the costs of each arm. 
Total costs (all drug and NHS costs) were £70.66 for the acupressure group, £111.13 for the standard care 
group and £161.92 for the sham acupressure group. However, caution is needed in interpreting these 
results because of very small changes in utility and the influence of a few high-cost outliers. A total of 26 
subjects from all three groups took part in in-depth qualitative interviews. Four themes emerged from the 
data: ‘Deciding to participate’, ‘Perceptions and experiences of complementary therapies’, ‘Experience of 
taking part in the trial’ and ‘Experience of using the wristbands’. The qualitative data overall suggested 
that the participants perceived the wristbands (both real and sham) as effective and helpful in managing 
their nausea experience during chemotherapy. Minor and transient side effects from the use of the 
wristbands were observed.
Conclusions
No clear conclusions can be made about the use of acupressure wristbands in the management of 
chemotherapy-related nausea and vomiting as the results did not reach statistical significance. However, 
the differences observed may be of clinical importance for patients and may potentially lead to lower 
health-care utilisation. The use of wristbands was safe and perceived to be effective by patients. Before 
rejecting this intervention we need to consider the therapeutic effect of placebos in situations such as the 
management of nausea, when low-cost and safe interventions may enhance the effect of antiemetic drugs 
even in the absence of clearly statistically significant effects. The study provided encouraging evidence 
in relation to an improved nausea experience as well as a suggestion of potential health resource-use 
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benefits; further consideration of the use of acupressure wristbands both in practice and in further clinical 
trials is therefore warranted.
Trial registration
This study is registered as ISRCTN87604299.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National 
Institute for Health Research.
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Chapter 1 Literature review
Existing research
Significant developments in antiemetic therapy over the past two decades have improved the control of 
chemotherapy-related vomiting. By contrast, chemotherapy-related nausea, both acute and delayed, is still 
a significant problem in clinical practice, with 42–52% of patients experiencing nausea on any one day in 
routine practice.1 Surprisingly, despite improvements in the management of vomiting, postchemotherapy 
nausea seems to have increased.2 Furthermore, clinicians often underestimate the experience of nausea, 
especially with regards to delayed nausea.3,4
Chemotherapy-induced nausea and vomiting can have a profound effect on the cancer treatment 
experience5 and is associated with negative effects on daily life and overall quality of life, including in 
relation to food intake, weight loss, social interactions, dehydration, difficulty with sleeping and anxiety.5,6 
In a qualitative study of patients’ experiences, unmanaged nausea was constant in some patients and 
made them exhausted for long periods after chemotherapy, making recovery between cycles longer.5 The 
impact of nausea is greater than that of vomiting,7 and nausea has proven to be more difficult to control. 
The direct and indirect costs of the experience of nausea and vomiting, especially of delayed symptoms, 
are considerable.8 Antiemetic trials have traditionally focused primarily on vomiting and emetic episodes, 
on which the effectiveness of many antiemetic drugs is judged. Little attention has been directed to the 
concept of chemotherapy-induced nausea despite the fact that it is increasingly recognised that nausea 
and vomiting are related but separate entities.9,10 The need for these two symptoms to be treated as two 
separate entities is strongly advocated.10
The reasons behind this incomplete management of chemotherapy-induced nausea and vomiting 
are multifaceted. They include health professionals’ limited understanding of the complex concept of 
chemotherapy-induced nausea and vomiting and its different phases; limited assessment in clinical practice 
of chemotherapy-induced nausea and vomiting and its risk factors; using more emetogenic chemotherapy 
protocols than in the past; not understanding clearly all the pathways involved in the development of 
chemotherapy-induced nausea and vomiting; and more focus given to the vomiting experience than 
nausea in clinical trials.11
As antiemetic medications do not fully control nausea during chemotherapy, non-pharmacological 
interventions in addition to antiemetics have been tested over the years, especially in the 1980s, including 
relaxation techniques, coping preparation, imagery and distraction techniques, with positive results in 
most studies.12 Acupuncture and its non-invasive form of acupressure have been tested several times after 
the classic early work of Dundee et al.13,14 In a literature search of MEDLINE, PubMed and Cumulative Index 
to Nursing and Allied Health Literature (CINAHL) using the key words ‘acupressure’, ‘nausea’, ‘vomiting’, 
‘emesis’, ‘chemotherapy’, ‘cancer’ and combinations, between 1990 and May 2005, we have identified 
10 studies specific to oncology, reported elsewhere,15 with 7 out of 10 studies showing positive results 
and a further two approaching statistical significance. These studies have used a variety of acupressure 
methods, such as the ReliefBand [a small battery-operated transcutaneous electrical nerve stimulation 
(TENS) device designed to stimulate the P6 acupoint];16–18 an acupressure wristband (a small elastic band 
with a round plastic button applying constant mild pressure on the P6 acupoint);19–21 and direct pressure 
on the P6 acupoint22 or P6 and ST36 acupoints together.23 Most studies had small sample sizes of 18–50 
patients. The largest study to date (n = 739) testing acupressure and acustimulation showed improvements 
in nausea and vomiting in men and a similar trend in women to reduce acute symptoms only, although 
the latter did not reach statistical significance.24 No improvement in nausea/vomiting was shown in a small 
study by Roscoe et al.25 in women with breast cancer using acustimulation (ReliefBand) wristbands. These 
two studies are suggestive of a possible gender effect. However, most past studies are hampered by small 
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sample sizes, the wide variety of (non-standardised) antiemetics used, differences in the risk factors for 
nausea and vomiting in these samples, the range of emetogenicity of chemotherapy regimens used and 
sampling issues. A recent Cochrane systematic review26 of the literature highlights that acupressure reduces 
acute nausea but not delayed nausea, and has no benefit for vomiting. However, the review was primarily 
focused on acupuncture rather than acupressure, all different methods of acupressure were examined 
together and the results regarding specifically vomiting are questionable (as many of the studies included 
in the review had samples with little, if any, vomiting across experimental and control groups).
Our own work
Over the past 8 years the lead applicant has developed a programme of research in the management of 
chemotherapy-induced nausea and vomiting that feeds into the current application. This has involved 
the assessment of the effectiveness of non-pharmacological interventions for the management of 
chemotherapy-induced nausea and vomiting including progressive muscle relaxation training and imagery 
techniques;27 pilot testing of acupressure;15 identification of risk factors for chemotherapy-induced nausea 
and vomiting development such as age, gender and anxiety;28,29 the management of anticipatory nausea 
and vomiting;30,31 the development of international clinical guidelines for managing chemotherapy-
induced nausea and vomiting32,33 and radiation-induced nausea and vomiting;34,35 exploration and further 
clarification of the concept of chemotherapy-induced nausea as a separate entity from vomiting;36 
assessment of chemotherapy-induced nausea and vomiting levels in current clinical practice in the 
UK;37,38 and development of a chemotherapy-induced nausea and vomiting-relevant clinical scale for the 
assessment of acute and delayed symptoms.39 This last is the only chemotherapy-specific scale available 
to date. In our qualitative study of the experience of chemotherapy-related nausea in 17 patients with 
cancer in the UK and USA,36 nausea was described as a distressing and complex symptom. Preliminary 
evidence indicates that nausea is part of a cluster of symptoms. Self-management techniques, such as 
dietary strategies and distraction techniques, were rooted in participants’ understanding of nausea and 
their beliefs about what caused nausea. Although self-management was common in almost all patients, 
acupressure was not one of the approaches used. In an observational prospective evaluation using 
patient self-reports, 102 patients with cancer receiving their first chemotherapy treatment participated.37 
Participants were followed up for four cycles of chemotherapy, providing a total of 272 assessments of 
nausea and vomiting. The results indicated that acute vomiting was experienced by 15.7% of the patients 
in cycle 1 and delayed vomiting by 14.7%, whereas acute nausea was present in 37.3% of the patients 
and delayed nausea in 47.1%, which increased over the four cycles. Moderately emetogenic chemotherapy 
had the highest incidence of chemotherapy-induced nausea and vomiting, and acute symptoms were 
more controlled than delayed symptoms. The data suggested that, although vomiting is relatively well 
controlled, nausea is a significant problem in practice; it also highlighted the high cost of inappropriate 
use of antiemetics, which was £17,524 for every 100 patients treated over four cycles.37
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Chapter 2 Research objectives
Primary objective
1. To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care 
compared with standard care with sham acupressure wristbands and standard care alone in the 
management of chemotherapy-induced (acute and delayed) nausea.
Secondary objectives
2. To assess the cost-effectiveness and extent of use of usual care in patients using acupressure 
wristbands in addition to standard care compared with that in patients receiving standard 
care with sham acupressure wristbands and standard care alone for the management of 
chemotherapy-induced nausea.
3. To assess the quality of life in patients using acupressure wristbands in addition to standard care 
compared with that in patients receiving standard care with sham acupressure wristbands and 
standard care alone in the management of chemotherapy-induced nausea and vomiting.
4. To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care 
compared with that in patients receiving standard care with sham acupressure wristbands and 
standard care alone in the management of chemotherapy-induced (acute and delayed) vomiting.
5. To ascertain for which emetogenic level of chemotherapy regimen (i.e. high, moderate or low) self-
acupressure using wristbands in addition to standard care is more or less effective in terms of nausea 
compared with patients receiving standard care with sham acupressure wristbands and standard 
care alone.
6. To ascertain whether or not any improvement in chemotherapy-induced nausea and vomiting from 
using acupressure wristbands is different between men and women.
7. To ascertain whether or not there is an age effect from the use of acupressure wristbands in relation to 
chemotherapy-induced nausea and vomiting.
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Chapter 3 Research methods
Design of the study
The study was a randomised controlled trial with three arms (Assessment of Nausea in Chemotherapy 
Research or ANCHoR). The three arms consisted of usual care plus (1) self-administered acupressure 
wristbands, (2) sham acupressure wristbands and (3) no additional treatment. The duration of the 
patients’ involvement was for four cycles of chemotherapy, as after four cycles patients not responding 
to the given chemotherapy may discontinue it, may be offered a different chemotherapy regimen or a 
different treatment plan, or may be offered supportive care only.
Subjects were allocated to the trial groups through computer-generated randomisation carried out 
remotely by the trials unit of the Christie NHS Foundation Trust, Manchester. The randomisation method 
used consisted of minimisation with a random element (stochastic minimisation), balancing for gender,29,40 
age (16–24, > 24–50, > 50 years)29,41 and three levels of emetogenic chemotherapy [low, moderate 
and high according to international American Society of Clinical Oncology (ASCO) and Multinational 
Association of Supportive Care in Cancer (MASCC) classifications].32,42
Biases were minimised through (1) exclusion criteria that leave out some of the factors and sources of 
nausea and vomiting in cancer patients other than chemotherapy (i.e. intestinal obstruction); (2) the use 
of covariates for variables that are closely linked with nausea and cannot be excluded as they are present 
in a large proportion of the population (i.e. anxiety),29,43 to be incorporated during the data analysis as 
a covariate in analysis of covariance (ANCOVA) models; and (3) the use of stratification for other key 
risk factors for nausea development during chemotherapy (i.e. age, gender) at the randomisation stage. 
Stratification, prior to randomisation, is important to ensure that known prognostic factors are equally 
distributed before measuring the treatment-related variables.
Pilot study using this design
We had carried out a two-arm pilot study of 36 breast cancer patients comparing acupressure wristbands 
(plus antiemetics) with standard antiemetics only.15 The present trial has been based on methods tested 
in this pilot study. Although it is acknowledged that this study was limited, key findings suggested that 
acupressure improved the nausea experience as well as nausea and vomiting occurrence and distress 
across the first 5 days of chemotherapy. Improvements were higher in relation to nausea than in relation to 
vomiting. Mean overall percentage of improvement (pre to post assessment) in the experimental subjects 
was 44.5%. The study showed that an acupressure trial is feasible, with high levels of compliance (only 
one patient stopped using the wristband, because of arm swelling), although one-third of the patients 
did not return completed assessments. The lack of follow-up techniques (i.e. reminder letters), which 
was due to time constraints, is partly responsible for this and is acknowledged as a limitation of the pilot 
study. However, missing data in the returned assessments were almost non-existent, and patient logs for 
acupressure usage were fully completed.
Sham acupressure and acupressure have also been used in another pilot trial that we have carried out 
recently for the management of cancer-related fatigue;44 patients in the sham group who were informed 
that they were receiving one of two combinations of (acu)points were blinded until the end of the trial 
and this group had little improvement compared with the real acupressure group, suggesting that this 
technique was a credible placebo and thus capable of minimising the likely effect of placebo on the 
study’s findings.
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Experimental and control interventions
The study was a Phase III pragmatic randomised trial.
The target population was a heterogeneous group of cancer patients meeting the inclusion criteria 
and about to receive chemotherapy of high, moderate and low emetogenic potential. Heterogeneity is 
important to address issues of response to different types of emetogenic chemotherapy, as well as by 
gender and age, as past literature highlights that these are important in assessing the effectiveness of 
treatments for chemotherapy-related nausea and vomiting. Minimally emetogenic chemotherapy was 
not included, as clinical guidelines recommend no antiemetic treatment and the nausea/vomiting level 
is < 10%.
In the acupressure group, in addition to standard antiemetics, patients were provided with a pair of widely 
available acupressure wristbands. These bands are elastic wristbands with a 1-cm protruding round plastic 
button (stud). They are available in two sizes, standard and large. Patients wore the wristband with the 
stud pressing the P6 acupoint, which is located on the anterior surface of the forearm, approximately a 
three-finger width up from the crease of the wrist between the tendons of the palmaris longus and flexor 
carpi radialis. An instruction sheet with a picture of acupoint P6 and how to locate the point was also 
provided to patients. Patients were provided with a pair of acupressure wristbands and instructed to wear 
them on both arms and take them off only when showering/bathing. Patients were instructed to wear 
the wristbands from the morning before chemotherapy administration and for the subsequent 6 days 
(total 7 days). No other complementary therapy use was recommended during the course of acupressure 
(although any such use was documented).
In the sham acupressure group, in addition to standard antiemetics, patients were provided with a pair of 
identical-appearing wristbands, with the only difference being that the sham wristband had the button 
on the exterior of the wristband and patients were instructed to wear the wristband with the button 
away from what is the P6 point. There has been an ongoing scientific debate on what constitutes an 
appropriate sham treatment, and it has been acknowledged that there is no sham method in acupuncture 
and acupressure studies that can be widely accepted as the optimal method. It is increasingly believed 
that sham acupuncture/acupressure designs cannot detect the whole placebo effect and may generate 
false-negative results,45–48 depending on the method used. We had debated the appropriateness of other 
sham methods but either they were not blinded enough for the purposes of the trial (i.e. they were 
slightly dissimilar to real acupressure wristbands) or they could be perceived as treatments themselves (i.e. 
acupressure at other points in the forearm or elsewhere where we had no information as to an effect on 
the experience of nausea). Patients in the clinics could also talk to each other and realise that they have 
different interventions or check the P6 point on the internet. Hence, we resolved to use an acupressure 
technique that appeared to be exactly the same as the active treatment with the only exception being 
the place of the stud on the wristband (interior or exterior to the band) used. This was also agreed 
by practitioners who had been consulted about their views on the most appropriate sham method. 
Furthermore, although it was acknowledged that many patients may have heard of the use of such 
wristbands, the results of our pilot study suggested that their knowledge of acupressure wristbands would 
be limited.15 In addition, the results of our qualitative study on self-management of chemotherapy-induced 
nausea and vomiting suggested that acupressure was not commonly used by patients.36 An assessment of 
blinding at the end of the trial was not conducted as patients had not been informed of the use of both 
sham and real acupressure bands during the trial, but had instead been informed that two different types 
of wristbands were being evaluated, with the approval of the ethics committee. Clinicians did not know 
the patients’ group allocation.
The control group received standard antiemetics alone. Standard antiemetics for all three groups were 
based on ASCO and MASCC international antiemetic guidelines with the exception of neurokinin 1 (NK1) 
receptor antagonists [e.g. aprepitant (Emend, Merck)] recommended in highly emetic chemotherapy, 
which were not available in the NHS. Hence, for highly emetic chemotherapy, patients received a 
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5-hydroxytryptamine type 3 (5-HT3) receptor antagonist [i.e. ondansetron 8 mg (Zofran
, GlaxoSmithKline)] 
and dexamethasone 8 mg intravenously before chemotherapy and the same orally for 3 days post 
chemotherapy; for moderately emetogenic chemotherapy a 5-HT3 receptor antagonist (ondansetron 
8 mg) and dexamethasone 8 mg intravenously before chemotherapy and a 5-HT3 receptor antagonist or 
dexamethasone for 2 days post chemotherapy; and for low emetogenic chemotherapy dexamethasone 
8 mg before chemotherapy and no other treatment post chemotherapy].32,42 All patients received rescue 
antiemetics if nausea and/or vomiting was persistent and they failed to respond to the antiemetic 
treatment (i.e. severe nausea or more than five vomiting episodes), based on the experience of each 
clinician (as agreed guidelines for rescue antiemetics had not been developed to date).
Inclusion/exclusion criteria
Inclusion criteria
 z Patients scheduled to receive their first chemotherapy cycle.
 z Patients scheduled to receive chemotherapy with high, moderate and low emetogenic potential (as per 
ASCO and MASCC classifications).
 z Patients scheduled to receive a chemotherapy regimen given as a single or a multiple administration 
repeated in 2-, 3- or 4-week cycles.
 z Patients who were acupressure wristband naive (in terms of never having tried for themselves such a 
wristband, although they may have seen or heard about such wristbands).
 z Patients of either gender and > 16 years.
 z Patients with any cancer diagnosis receiving chemotherapy without concurrent use of radiotherapy.
 z Patients receiving chemotherapy as outpatients or inpatients.
 z Patients who were willing to participate in the study and be randomised into one of the three 
study groups.
Exclusion criteria
 z Patients scheduled to receive radiotherapy concurrently with chemotherapy.
 z Patients unable to self-care (i.e. unable to use wristbands appropriately; mental incapacity preventing 
continuous and optimal use of wristbands) as judged by the investigators.
 z Patients with liver disease (as nausea is a common presenting symptom).
 z Patients with metabolic risk factors for nausea (i.e. electrolyte imbalances causing nausea/vomiting).
 z Patients with mechanical risk factors for nausea (i.e. intestinal obstruction).
 z Patients experiencing nausea and/or vomiting resulting from the use of opioids.
 z Patients with lymphoedematous arms.
 z Patients with chronic alcohol use (chronic alcohol use is associated with minimal levels of nausea and/
or vomiting).
Proposed sample size
In our pilot study15 the mean score for nausea experience averaged over 5 days was 2.79 [weighted 
average standard deviation (SD) 3.15] in the control group and 1.45 (weighted average SD 2.76) in the 
intervention group. At least 135 participants per arm would be required to detect this pair-wise difference 
between arms using a t-test with a conservative Bonferroni-adjusted significance level of 0.05/3 = 0.017 
at a power of 90%. The pilot study suggested an attrition rate of 33% and so, initially, at least 202 
participants would be required per arm. As the SDs are much larger than the means in the pilot data, 
they are suggestive of highly skewed distributions; hence, the equivalent non-parametric test (the Mann–
Whitney test) will be used. As the asymptotic relative efficiency of the Mann–Whitney test is at worst 
0.864, the sample size for a Mann–Whitney test is equal, in the worst case, to the sample size for the 
t-test divided by 0.864. This would increase the required sample size to 156 per arm before attrition and 
233 after attrition, equalling 699 across the three arms.
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Recalculation of sample size requirements during the trial
Because of a slower recruitment rate than envisaged initially, it was felt necessary to reconsider the 
sample size requirements. The Clinical Trials Unit analysed the first 141 cases that provided complete 
data over all four cycles. The SD for this cohort of patients was 2.75, slightly lower than the SD of 3 that 
we included in the initial power calculations. We had also calculated the power of the study to 90%, 
whereas the standard power in most studies is 80%. We adjusted the power down to 80%, which is the 
standard power accepted. With these adjustments the sample required was 480 participants. This change 
was agreed with both the Data Monitoring and Ethics Committee (DMEC) and the Health Technology 
Assessment (HTA) programme.
There were 361 cases with data on the primary outcome (117, 118 and 126 in the standard care only, 
sham acupressure and real acupressure arms respectively). Pair-wise trial arm comparisons were planned 
and as the data were skewed a non-parametric test (Mann–Whitney) was used, and this has an asymptotic 
relative efficiency of at worst 0.864 compared with the t-test. Thus, our effective sample sizes are around 
117 × 0.864, which is about 100. With such a sample size there is approximately 80% power to detect a 
standardised difference in means of 0.46 in a two-tailed test at the 0.017 level of significance.
Recruitment took place in the largest single-site cancer centre in the UK and cancer units or centres of 
district general hospitals and university hospitals, including the Christie NHS Foundation Trust and its 
peripheral clinics where chemotherapy is administered (Royal Oldham Hospital, Tameside General Hospital, 
Leighton Hospital, Stepping Hill Hospital at Stockport, Macclesfield District General Hospital, North 
Manchester General Hospital), the Royal Liverpool Hospital, Clatterbridge Centre for Oncology, St Helens 
Hospital, Southport General Infirmary and three cancer units associated with the University of Plymouth 
(South Devon Healthcare NHS Foundation Trust, Plymouth Hospitals NHS Trust, Royal Cornwall Hospitals 
NHS Trust). Available statistics from the Christie NHS Foundation Trust alone had shown that around 
9000 patients receive chemotherapy every year, with approximately two-thirds of these patients receiving 
chemotherapy in 3-week cycles. Recruitment rates were based on a similar antiemetic study that we had 
conducted over four cycles of chemotherapy,37 which had taken 6 months to recruit 102 patients, with 
65% retained over the four cycles of chemotherapy. Based on similar recruitment levels at each of the 14 
sites listed above, we had estimated that recruitment would be completed in 16 months, with a further 
3 months required to complete the follow-up of the final patients. Three dedicated researchers and 30 
cancer network research nurses recruited patients and collected the data. Data collection was audited 
regularly and discussed with the Trial Steering Committee and the DMEC.
Statistical analysis
Descriptive statistics have been estimated for all baseline sociodemographic and clinical variables by arm 
and for outcome variables (scores on nausea and vomiting subscales) by arm. The association between 
baseline sociodemographic or clinical variables and outcome variables has been assessed using between-
group tests or correlations depending on skewness. Primary outcome variables have been compared 
between the arms using t-tests, one-way analysis of variance (ANOVA), Mann–Whitney tests and Kruskal–
Wallis tests, bearing in mind any skewness in the data. Ordinal regression models were employed to permit 
covariate-adjusted analyses of a grouped version of the primary outcome. An extension of the proportional 
odds regression model was used for longitudinal analyses over cycles and this was fitted with a generalised 
estimating equation (GEE) approach. An intention-to-treat analysis model has been followed. As the 
primary outcome variable was assessed over several days repeatedly, an aggregate score of all assessments 
in each cycle was calculated before any modelling analysis.
The effect of missing values was assessed by comparing the numbers and percentages of participants with 
missing values in the three arms of the study; differences in baseline variables between participants with 
observed and missing outcomes in each arm; and, for participants with observed outcomes, differences 
in baseline variables between the three arms. There were no clear associations between known predictors 
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of nausea and cases missing the nausea primary outcome. This fact along with the highly non-normal 
distribution of the primary response (for which imputation methods are not so well developed) informed 
our decision not to apply multiple imputation analyses.
Randomisation method
The trial arm allocation method was minimisation with a random element over the margins of three 
factors: gender, age (16–24, > 24–50, > 50 years) and emetogenic risk (low, moderate, high). The first 20 
cases were allocated completely at random and thereafter the allocation probability vector was (0.6, 0.3, 
0.1) to the arms that would result in the least to the most imbalance respectively. Researchers telephoned 
the randomisation office staff with the patient details and the staff used an in-house program to obtain 
the allocated trial arm.
Outcome measures
Primary outcome
Rhodes Index of Nausea, Vomiting and Retching
The Rhodes Index of Nausea, Vomiting and Retching49 is an eight-item validated scale measuring nausea 
and vomiting experience, incidence and severity. In this study the nausea experience subscale has been 
used (as shown in Appendix 1) for power calculations of the sample size, using the mean score across 
all assessment days in each cycle as the end point. From the nausea experience score, incidence and 
severity can also be isolated. Scores can range from 0 to 12, with higher scores indicating higher levels 
of the symptom experience. This scale, taking 1–2 minutes to complete, was scored daily from the day 
before chemotherapy (to capture any anticipatory nausea) up to 7 days post chemotherapy, that is, eight 
assessments per cycle.
Secondary outcomes
Multinational Association of Supportive Care in Cancer Antiemesis Tool
The MASCC Antiemesis Tool (MAT)39 is an eight-item scale that assesses in a simple way both acute and 
delayed nausea and vomiting incidence and extent and was designed specifically for chemotherapy-related 
nausea and vomiting. This short clinical scale has shown satisfactory internal reliability (alpha = 0.77), 
contrasted-groups and concurrent validity, and high recall of events up to 3 weeks post chemotherapy. 
The MAT is designed to be used once per cycle, with retrospective patient recall of events, minimising 
the patient burden. Factor analysis has clearly identified three factors, namely vomiting, acute 
nausea and delayed nausea.39 The scale (see Appendix 2) was completed at day 10 of each cycle (i.e. 
four assessments).
Functional Assessment of Cancer Therapy – General quality-of-life scale
The Functional Assessment of Cancer Therapy – General (FACT-G)50 is a well-validated quality-of-life scale 
focusing on functional assessment. This functional scale has provided not only quality-of-life indications, 
but also changes in other symptoms/side effects that may have resulted from any improved management 
of nausea (e.g. appetite). High internal consistency and construct validity have been reported in past 
studies using the FACT scales in various cancer populations. Completion time is about 5 minutes. This scale 
(see Appendix 3) was completed at baseline and then at day 10 of each cycle (i.e. five assessments).
Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale51 is a 14-item scale assessing anxiety with seven items and 
depression with a further seven items. Each item is answered on a 4-point scale (0–3). Scores on each 
subscale thus range between 0 (no symptoms) and 21 (numerous and severe symptoms). There are 
separate scores for anxiety and depression. In this study the anxiety subscale was obtained at baseline (see 
Appendix 4), with the score used as a covariate in the final statistical analysis of the data, as anxiety is a 
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key risk factor for the development of nausea/vomiting.29,43 This scale has been used extensively with cancer 
patients as a screening tool and has been reported to have excellent psychometric properties. Completion 
time is approximately 2–5 minutes.
Patient expectations of nausea/vomiting
As this is a key risk factor identified in the literature,29,43 a two-item scale was developed assessing patient 
expectations for nausea and vomiting, measured on a 10-point ordinal scale. We have used the same 
measurement approach elsewhere in the past52 although no validation of these two items has formally 
taken place. This was incorporated in the final analysis of outcomes. Patients were also asked how much 
they believed that the acupressure wristbands had helped them alleviate nausea and how much faith they 
had in complementary therapies, also using 10-point scales (see Appendix 5).
Sociodemographic and disease/treatment variables
Sociodemographic and treatment characteristics were obtained from the patients’ records and the patients 
themselves (see Appendix 6). These included gender, age, educational level, marital status, experience 
with nausea in the past (such as during pregnancy, motion sickness or nausea when eating certain foods), 
use of/experience with other complementary therapies in the past, cancer diagnosis, stage of disease 
and chemotherapy protocol used and dosage. Such a questionnaire had already been developed by the 
team and used in the past in other nausea/vomiting studies.15,29 Medication use (standard and rescue 
antiemetics) during study participation was obtained from pharmacy records. Furthermore, although not 
formally required, researchers asked patients about any side effects (or patients could volunteer side effect 
information) and these were recorded in a descriptive manner.
Assessment scales were provided to patients for self-completion at home; completed forms were returned 
to researchers using a prepaid self-addressed envelope. Patients were asked to complete their daily 
assessments of nausea at the same time in the evening to have a consistent time frame for measuring 
change. Patients were reminded to return their completed scales when attending for chemotherapy and 
were also contacted at an early stage during the trial when the researcher would remind them of the 
instructions for completing and returning the scales. Table 1 shows the timing of the completion of the 
study assessment forms.
TABLE 1 Timing of completion of study assessment forms
Assessment scale
Baseline 
assessment
Chemotherapy 
days –1, 0, 1, 2, 3, 
4, 5, 6 × four cycles
Chemotherapy 
day 10 × four 
cycles
End of study 
participation
Rhodes Index of Nausea, Vomiting and 
Retching
7
MAT 7
FACT-G 7 7
Hospital Anxiety and Depression Scale 7 7
Patient expectations questionnaire 7
Sociodemographic variables 7
Disease/treatment variables 7 7
Health economics assessment 7 7 7 7
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Molassiotis et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17260 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 26
11
Wristband compliance and audit
Patients who had been randomised to the acupressure and sham acupressure groups were also asked 
to provide information about the length of time that they had worn their wristbands on the day of 
chemotherapy and the 6 subsequent days. A wristband compliance questionnaire (see Appendix 7) was 
given to the patients per cycle to complete and return in the prepaid envelope together with the other 
completed scales.
In addition to compliance with wearing wristbands, it was important to determine whether or not patients 
were wearing the wristbands correctly according to the instructions they had been given. A wristband 
audit was conducted at two Manchester sites (Christie NHS Foundation Trust and Macclesfield District 
Hospital) and two Liverpool sites (Clatterbridge Centre for Oncology and the Royal Liverpool Hospital). 
Research nurses who were involved with patient recruitment to the trial assessed how correctly patients 
were wearing their wristbands when they attended for chemotherapy treatment. In total, observations 
were carried out for 35 pairs of wristbands. An audit proforma is shown in Appendix 8.
The trial did not come under Medicines and Healthcare products Regulatory Agency (MHRA) regulations 
as it was not a clinical trial of an investigational medicinal product as defined by EU Directive 2001/20/
EC; a procedure for the reporting of serious adverse events was therefore not required. However, patients 
were regularly asked about their experiences with regard to wearing wristbands (e.g. when attending for 
chemotherapy and during routine telephone communication during the trial) and about any problems 
associated with the wristbands (e.g. if a larger size was required, if the wristband caused any kind of 
discomfort, if the wristband became damaged). These were logged by the researchers, with appropriate 
advice offered to patients.
Measurement of costs
Costs were identified, measured and valued using a microcosting approach (in which each component 
of resource use was identified, estimated and a unit cost derived from market prices and national 
estimates53). The cost analysis was performed from the perspective of the health service provider and from 
a societal perspective. Included in the health-care provider costs were those accrued by the acute trusts 
and the primary care trusts. Costs to the patients and their families, including social care, were considered 
as the additional costs for society. Indirect costs in terms of workdays lost were also included.
Data were collected prospectively and retrospectively using multiple sources including patient records and 
patient self-reported questionnaires (see Appendices 9 and 10). The questionnaires reported health service 
utilisation subsequent to and as a result of chemotherapy-induced nausea/vomiting (e.g. GP visits), patient 
out-of-pocket expenses such as over-the-counter medicines or transport and the use of services in the 
social sector such as home help and support from family and friends. Valuation of resource items including 
hospital resources (e.g. bed-days and staff time) and community resources (e.g. GP visits, home help) 
was carried out using national estimates;53 market prices were assigned to medication; non-market items, 
specifically patient time and informal help provided by family and friends, were valued using market wage 
rates; and out-of-pocket expenses (e.g. bus fares) were also calculated.
In more detail, direct medical costs were defined as the costs of prophylactic or rescue antiemetic 
medications, drug administration devices, staff time associated with preparing and administering 
medication and tending to patients with chemotherapy-induced nausea and vomiting, hospitalisations 
due to chemotherapy-induced nausea and vomiting, hospital outpatient or GP visits due to chemotherapy-
induced nausea and vomiting and over-the-counter medications or other complementary therapies. Direct 
non-medical costs were those for transportation and need for assistance, such as additional childcare. 
Indirect costs were based exclusively on the number of workdays lost due to chemotherapy-induced 
nausea and vomiting. Costs that were not included in this evaluation were costs for chemotherapy agents, 
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preplanned visits or hospitalisations for the purpose of chemotherapy administration, and diagnostic 
and laboratory tests, and other patient management costs not directly related to chemotherapy-induced 
nausea and vomiting.
Analysis of economic data
The total cost of each arm of the trial was calculated by combining the resource use and unit cost data. 
No discounting was necessary given the time period of data collection (< 1 year). Sensitivity analysis 
was carried out to account for uncertainty when estimates of cost data were used. Differences in costs 
between the three arms were tested for using independent sample t-tests. Cost data in each of the 
arms were analysed alongside the quality-of-life measures with the data combined and analysed using 
cost-effectiveness ratios (i.e. the difference in costs between alternatives relative to the difference in 
effectiveness between the same alternatives). Cost per quality-adjusted life-year (QALY) data are presented.
Nested qualitative study
There was an exploratory nested qualitative study within the trial that explored patients’ reasons for 
consenting to take part in the trial and their experiences of participating in a randomised controlled trial 
for acupressure wristbands.
A number of qualitative studies have explored patients’ experiences of receiving treatment with 
acupuncture, and their findings have suggested that the treatment is associated with eliciting benefits 
beyond the alleviation of the patients’ presenting condition.54–56 These expanded effects of care include 
improvements in physical/mental health and emotional well-being and changes in personal identity 
and lifestyle, and can result in patients ‘feeling normal again’ and ‘regaining their lives’. Despite the 
burgeoning qualitative research exploring the experiences of patients receiving acupuncture, to date no 
study has been conducted to explore the experiences of users of acupressure or acupressure wristbands. To 
address this gap in the evidence base, a nested qualitative study was conducted with patients taking part 
in the main trial.
Objectives
1. To outline patients’ experiences of using acupressure wristbands.
2. To outline the reasons why patients consent to take part in a clinical trial of acupressure wristbands.
3. To outline patients’ experiences of taking part in a randomised controlled trial of 
acupressure wristbands.
Sample
A purposive sample of patients who had taken part in the clinical trial of the effectiveness and cost-
effectiveness of acupressure wristbands for chemotherapy-induced nausea and vomiting participated in 
one-to-one semistructured interviews. Patients were recruited from each of the three geographical sites, 
represented all three study arms, had either high or low scores for the item about their expectation of 
effect from the wristbands and either had or did not have experience using complementary therapies 
in general.
Methodology
Interviews were conducted by three members of the research team and were directed by a topic guide. 
Topic guides were updated throughout the study to incorporate emerging themes. Interviews were 
audiotaped and transcribed verbatim. Interviews lasted for between 30 and 70 minutes. Transcripts were 
analysed thematically using framework analysis, a manual, matrix method, which facilitates thematic and 
cross-case interpretation.57,58 Analysis proceeded in five stages:
1. familiarisation – transcripts were read and reread by members of the research team until they became 
familiar with and immersed in the data
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2. identification of the thematic framework – key issues, concepts and themes arising from the data were 
identified and grouped thematically to construct a conceptual framework
3. indexing – two of the research team independently applied the thematic framework to the same 
transcript to explore any differences in application; the thematic framework was then applied 
systematically to all of the data
4. charting – thematic matrices were constructed for all identified categories/subcategories to further 
summarise and synthesise the indexed data
5. detection, categorisation and classification – the original research questions were reconsidered and 
the charts examined in order to define concepts, map the range and nature of phenomena, find any 
associations and provide explanations.
Research governance
The sponsor of the study was the University of Manchester. The MHRA has confirmed that this trial does 
not fall under the Medicines for Human Use (Clinical Trials) Regulations 2004, as described earlier.
Trial Steering Committee
A Trial Steering Committee was formed, which was chaired by a patient representative. Other members 
included a medically trained expert in chemotherapy nausea who was independent of the study, an 
acupressure practitioner, a representative of the trials unit (statistician), the lead applicant and two of 
the co-applicants, one of whom was the study’s user/co-applicant. This committee was responsible for 
trial safety and assurance of scientific validity and was convened four times: once after completion of the 
preparatory part of the trial, twice more during the recruitment phase and once after data cleaning and 
before data analysis.
Data Monitoring and Ethics Committee
An independent DMEC was set up by the Christie NHS Foundation Trust Clinical Trials Unit in accordance 
with standard procedures to review accruing trial data on a regular basis and also to ensure that a 
sufficient number of patients were enrolled, reporting back to and guiding the Trial Steering Committee 
and also reporting to the HTA programme through the Trial Steering Committee. The members of this 
committee were not linked to the study in any way.
Trial management
The Christie NHS Foundation Trust Clinical Trials Unit was responsible for data management. It is based 
within the research and development division of the Christie NHS Foundation Trust. The unit manages 
international, national and local studies and its portfolio during the conduct of our trial included three 
international studies, 14 randomised studies and 12 other studies. These included a number of studies 
with funding from Cancer Research UK through the Clinical Trials Advisory and Awards Committee (CTAAC) 
route. The unit has a strategic alliance with the Medical Research Council Clinical Trials Unit in London, and 
the development and operation of the Christie unit is supported by the MRC unit.
The Clinical Trials Unit has robust governance and management systems that have been subjected to a 
MHRA Good Clinical Practice inspection, with the inspectors describing the systems for the management 
of clinical trials as ‘robust’. This study was conducted in accordance with the unit’s standard operating 
procedures; these cover all aspects of the management of clinical trials and the unit can assure funders 
that the studies supported are managed within a quality framework that has been reviewed by the 
MHRA. The unit has been responsible for the monitoring of the trial to ensure that it is conducted in 
accordance with the protocol, research governance framework and applicable regulations. A full list 
of standard operating procedures is available on request and on the unit’s website. The unit had the 
capacity and capability to support a trial of this nature (indeed it has in its portfolio another national 
study on complementary therapies using acupuncture) and was able to identify a project lead to oversee 
the work of the data manager. The data manager was responsible for ensuring that the data generated 
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by the study were reviewed appropriately by the DMEC, and the trials supported by the unit are typically 
reviewed through these mechanisms. Randomisation and statistical analysis have been supported by the 
unit’s statisticians.
Service user involvement
Service users were involved at three levels. The first has been at the development phase of this proposal, 
with the contribution of the chairperson of the National Cancer Research Institute (NCRI) Consumer 
Liaison Group, who was a named co-applicant in the study, and reviews by expert patients. The second 
level was monitoring the trial project and guiding it within its scientific framework through chairing and 
participating in the Trial Steering Committee and the DMEC. Finally, users have advised us in planning 
appropriate patient-focused dissemination of the trial results at the end of the study. For reviews, contacts, 
active involvement and access, the research partners’ strategy and mechanisms through the NCRI Cancer 
Experiences Collaborative have been utilised.
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Chapter 4 Main findings
Patient recruitment
Three main study centres were involved in patient recruitment, namely Manchester, Liverpool and 
Plymouth. Recruitment began with a month-long pilot phase in Manchester at the Christie NHS 
Foundation Trust to test recruitment processes. The first case was randomised on 23 March 2009. A 
phased recruitment launch followed in the two remaining centres with patient recruitment starting in 
Liverpool in May 2009 and in Plymouth in June 2009. The last case was randomised on 15 October 2010. 
In total, 14 hospital sites were involved in recruitment (Table 2) and 500 cases were randomised (166 
standard care, 166 sham acupressure and 168 acupressure).
Monthly recruitment for the trial is given in Figure 1.
A CONSORT flow diagram (Figure 2) shows the numbers of participants recruited and randomly 
assigned to the three trial arms and who received the intended interventions and were analysed for the 
primary outcome.
Descriptive statistics by trial arm
The majority of the participants were female, married and aged > 50 years. The key diagnoses of the 
sample included breast and colorectal cancer and the majority had received moderately emetogenic 
chemotherapy (including anthracycline-based chemotherapy). Other sociodemographic and clinical data 
are provided in Table 3.
TABLE 2 Trial recruitment per study site
Main centre and total number of 
patients recruited Breakdown of recruitment per study site
Manchester (244 patients randomised 
over 76 weeks)
119 from Christie NHS Foundation Trust (including initial pilot phase)
50 from Royal Oldham Hospital
1 from Tameside General Hospital
5 from Leighton Hospital
39 from Stepping Hill Hospital
26 from Macclesfield District General Hospital
4 from North Manchester General Hospital
Liverpool (161 patients randomised 
over 71 weeks)
33 from Clatterbridge Centre for Oncology
79 from Royal Liverpool Hospital
41 from St Helens Hospital
8 from Southport General Infirmary
Plymouth (95 patients randomised over 
64 weeks)
2 from Torbay District General Hospital
88 from Derriford Hospital
5 from Royal Cornwall Hospital
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Assessment of missing data for the primary outcome
A total of 500 cases were randomised, but there are data for only 361 of these cases for the primary 
outcome, i.e. the primary outcome is missing in around 28% of cases. Table 4 illustrates, for the remaining 
497 cases, the proportion of cases in which the primary outcome is missing by various factors thought to 
influence nausea propensity (three cases were allocated to ‘No acupressure’ but there are no records in 
the trial database for these three cases, i.e. no completed screening forms and no returned data form). 
There are no marked associations between any of these factors and the probability of the primary outcome 
being missing.
Inevitably there is a further dropout of cases with each cycle, as illustrated in Table 5.
Table 6 shows the mean nausea experience of the patients using the Rhodes Index of Nausea, Vomiting 
and Retching scale. Scores range from 0 to 12, with higher scores indicating higher levels of nausea. 
Both the sham and acupressure arms experienced less nausea than the standard care arm, although 
the difference did not reach statistical significance. It is important to note that these mean values 
represent very low levels of nausea. Only at cycle 4 did the results become significant (p < 0.05), with the 
acupressure group reporting no nausea experience.
Tables 7 and 8 show the frequencies of the nausea and vomiting experience, respectively, categorised over 
five ranges of experience.
Tables 9 and 10 present descriptive data of acute and delayed nausea, respectively, based on the MAT 
scale, showing similar results to those obtained with the Rhodes Index of Nausea, Vomiting and Retching 
scale. Tables 11 and 12 report the data for acute and delayed vomiting, respectively, based on the 
MAT scale.
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FIGURE 1 Trial recruitment by month. Monthly target accrual was recalculated after sample size adjustment in May 
2010, with the agreement of the HTA team. Power was initially calculated to 90% but as recruitment was slower than 
expected the sample size was recalculated to 80% power.
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TABLE 3 Sociodemographic and clinical data of the sample
None (n) Sham bands (n) Acupressure bands (n)
Gender
Male 38 37 39
Female 128 129 129
Age group (years)
≤ 50 51 55 54
51+ 115 111 114
Marital status
Single 18 15 24
Married 85 83 88
Divorced or separated 20 27 21
Widowed 13 16 11
Missing 30 25 24
Educational attainment
Primary school 0 3 2
Secondary school 68 74 69
College/diploma 37 26 43
University/degree 20 14 17
Postgraduate 6 12 8
Missing 35 37 29
Ethnic origin
Caucasian 111 110 121
Black 0 1 2
Asian/Chinese 2 2 2
Mixed 1 3 0
Missing 52 50 43
Religious affiliation
Christian 114 106 122
Muslim 1 2 3
Hindu 0 1 0
None 17 18 12
Prefers not to say 1 4 2
Other 5 8 7
Missing 28 27 22
Occupational group
Professional 40 44 36
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None (n) Sham bands (n) Acupressure bands (n)
Managerial and technical 17 16 23
Skilled non-manual 14 11 16
Skilled manual 14 12 11
Unskilled 14 16 15
Not applicable 28 33 43
Missing 39 34 24
Occupational status59
Employed full-time 50 36 33
Employed part-time 22 17 26
Retired 46 50 51
Unemployed 2 4 3
Casual worker 0 0 1
Not working due to ill health 10 20 17
Housewife 5 11 10
Other 2 3 4
Missing 29 25 23
Smoking history
Never 63 62 66
Previously 56 51 62
Current 20 25 18
Missing 27 28 22
Cancer diagnosis
Breast 89 90 82
Bowel (colon and rectum) 25 27 19
Gynaecological 20 15 21
Lung 7 10 21
Lymphoma 6 2 7
Oesophagus 4 5 2
Stomach 2 3 1
Pancreas 1 1 4
Melanoma 2 2 1
Bladder 1 1 2
Gall bladder 0 1 1
Head and neck 1 1 0
continued
TABLE 3 Sociodemographic and clinical data of the sample (continued)
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None (n) Sham bands (n) Acupressure bands (n)
Endocrine/thymus 0 1 1
Prostate 1 0 1
Child: Ewing’s sarcoma 1 1 0
Child: non-Hodgkin’s lymphoma 0 1 0
Missing 6 5 5
Emetogenic risk
Low 13 11 12
Moderate 107 111 111
High 46 44 45
TABLE 4 The proportion of cases missing primary outcome data by various factors
Factor Level Missing primary outcome, n/N (%) p-valuea
Trial arm None 46/163 (28)b 0.69
Sham bands 48/166 (29)
Acupressure bands 42/168 (25)
Age (years) ≤ 50 42/160 (26) 0.78
51+ 94/337 (28)
Gender Male 35/114 (31) 0.43
Female 101/383 (26)
Emetogenic risk Low 12/36 (33) 0.69
Moderate 87/327 (27)
High 37/134 (28)
2-weekly CT No 122/451 (27) 0.75
Yes 14/46 (30)
Baseline anxiety (83 missing) Normal (0–7) 50/250 (20) 0.16
Borderline (8–10) 22/76 (29)
Case (11–21) 24/88 (27)
Nausea expectation (84 
missing)
0–3 24/100 (24) 0.80
4–6 52/224 (23)
7–10 18/89 (20)
a Chi-squared tests of equal proportions.
b Three cases were allocated to ‘No acupressure’ but there are no records in the trial database for these three cases, i.e. 
no completed screening forms and no returned data forms.
TABLE 3 Sociodemographic and clinical data of the sample (continued)
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TABLE 5 Dropout data by trial arm over the four cycles of chemotherapy
Dropout status None Sham bands Acupressure bands Total
Immediate (no outcome data) 45 47 36 128
Complete (all outcome data) 80 76 82 238
Cycle 1 then dropped out 12 14 14 40
Cycles 1 and 2 then dropped out 11 17 12 40
Cycles 1–3 then dropped out 14 11 12 37
Intermittent data 4 1 12 17
Total 166 166 168 500
TABLE 6 Mean Rhodes Index of Nausea, Vomiting and Retching nausea experience (days 0–6)
Cycle Nonea Sham bandsa Acupressure bandsa
1 1.43 (0, 0, 3.71, 8.57) (n = 117) 0.57 (0, 0, 2.64, 9.17) (n = 118) 1.0 (0, 0, 2.97, 7.50) (n = 126)
2 1.71 (0, 0, 3.43, 10.14) (n = 109) 0.71 (0, 0, 2.14, 10.29) (n = 105) 0.93 (0, 0, 3.43, 9.57) (n = 114)
3 1.14 (0, 0, 3.86, 11.86) (n = 96) 0.71 (0, 0, 2.29, 9.71) (n = 88) 0.43 (0, 0, 3.00, 10.14) (n = 103)
4 1.14 (0, 0, 4.00, 9.14) (n = 81) 0.43 (0, 0, 2.43, 8.57) (n = 77) 0.00 (0, 0, 1.82, 9.86) (n = 90)
a Data are median (min., lower quartile, upper quartile, max.)
TABLE 7 Numbers of participants in each nausea experience score range (based on Rhodes Index of Nausea, Vomiting 
and Retching nausea experience subscale, days 0–6)
Score
0 (0–2] (2,4] (4,6] > 6 NA
Cycle 1
None 34 35 21 14 13 49
Sham bands 36 47 19 8 8 48
Acupressure bands 41 38 28 11 8 42
Cycle 2
None 32 29 27 9 12 57
Sham bands 36 41 13 10 5 61
Acupressure bands 43 29 19 10 13 54
Cycle 3
None 33 22 19 14 8 70
Sham bands 33 31 10 9 5 78
Acupressure bands 43 29 11 8 12 65
Cycle 4
None 27 23 13 10 8 85
Sham bands 36 16 15 7 3 89
Acupressure bands 53 17 8 6 6 78
NA, no data available.
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TABLE 8 Numbers of participants in each vomiting experience score range (based on Rhodes Index of Nausea, 
Vomiting and Retching vomiting experience subscale, days 0–6)
Score
0 (0–1] (1,2] (2,3] > 3 NA
Cycle 1
None 76 24 11 4 3 48
Sham bands 80 27 7 3 1 48
Acupressure bands 85 24 9 7 1 42
Cycle 2
None 74 20 9 2 3 58
Sham bands 74 21 6 4 0 61
Acupressure bands 90 16 2 4 2 54
Cycle 3
None 75 13 3 0 5 70
Sham bands 68 15 4 0 1 78
Acupressure bands 81 15 3 1 3 65
Cycle 4
None 60 11 3 5 2 85
Sham bands 61 12 1 2 1 89
Acupressure bands 76 9 3 1 1 78
NA, no data available.
Primary outcome analysis
The primary outcome is the mean nausea experience (days 0–6) for cycle 1 measured using the Rhodes 
Index of Nausea, Vomiting and Retching scale. As can be seen from Figure 3 the data are highly skewed. 
The possible range of scores is from 0 to 12, but, in fact, 111/361 (31%) are exactly zero and around half 
of all values are < 1. No transformation would be successful in normalising such a distribution.
The distribution by trial arm is shown in Figure 4. Because of the highly skewed distribution, the non-
parametric Kruskal–Wallis test has been used for the primary comparison of the trial arms. This overall test 
is non-significant (p = 0.14).
Provision for pair-wise comparisons (Mann–Whitney U-tests) with a Bonferroni adjustment was made 
in the trial design: none compared with acupressure (p = 0.23), none compared with sham acupressure 
(p = 0.05), sham acupressure compared with acupressure (p = 0.40). It should be noted that the 
reference value for statistical significance is 0.017 and so none of these pair-wise comparisons is 
statistically significant.
Regression analyses for the nausea primary outcome data
As noted previously, the data are highly skewed and no transformation will be successful in normalising 
the distribution. The approach adopted here is to group the values into five ordered categories and to 
utilise regression methods for ordinal data. The categories were chosen after inspection of Figure 3. The 
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TABLE 9 Multinational Association of Supportive Care in Cancer Antiemesis Tool – acute nausea: numbers of 
participants reporting a score from 0 to 10
Score
0 1–3 4–6 7–9 10 NA
Cycle 1
None 63 20 14 11 9 49
Sham bands 65 33 9 8 5 46
Acupressure bands 72 29 14 8 7 38
Cycle 2
None 56 28 14 6 6 56
Sham bands 71 21 4 8 2 60
Acupressure bands 68 25 7 8 8 52
Cycle 3
None 52 24 10 7 3 70
Sham bands 53 21 9 4 2 77
Acupressure bands 65 15 10 8 4 66
Cycle 4
None 44 17 10 7 3 85
Sham bands 49 16 8 5 1 87
Acupressure bands 61 12 8 4 3 80
NA, no data available.
first category, ‘Zero’, was chosen as it represented no nausea at all and a large fraction of cases fell into 
this category (31%). The choice of the other categories was somewhat arbitrary. Five categories is fairly 
typical for ordinal regression models in the literature and it is desirable that no category has a very small 
frequency. Category 5 has a broad range but includes only 8% of cases; subdividing it further would be 
counterproductive. Having chosen the lowest and highest categories the remaining three were simply 
selected to have equal width. Table 13 shows the categories and the frequencies by trial arm (n = 361).
The main tool used was the proportional odds regression model:60
Logit[Pr(Yi ≤ k/xi)] = αk + β
Txi (1)
where k = 1, 2, 3, 4 denotes category; i = 1, 2, . . ., n denotes case; Yi is the response category for the ith 
case; xi is a vector of covariate values for the ith case (including the trial arm); αk is an intercept term for 
the kth category; β is a vector of parameters to be estimated; and Logit(p) = log[p/(1 – p)].
Unadjusted fit
The snippet of output in Table 14 is for an unadjusted fit using all of the available data (n = 361).
These data show that:
 z the likelihood ratio test of the proportional odds assumption is non-significant (p = 0.51) meaning 
that there is no good evidence against this assumption
 z the likelihood ratio test for the trial arm effects is non-significant (p = 0.34)
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TABLE 10 Multinational Association of Supportive Care in Cancer Antiemesis Tool – delayed nausea: numbers of 
participants reporting a score from 0 to 10
Score
0 1–3 4–6 7–9 10 NA
Cycle 1
None 49 24 21 13 11 48
Sham bands 61 25 14 7 9 50
Acupressure bands 58 30 25 8 7 40
Cycle 2
None 43 23 22 11 6 61
Sham bands 54 24 17 7 2 62
Acupressure bands 57 28 17 9 5 52
Cycle 3
None 43 22 15 8 5 73
Sham bands 42 26 14 4 3 77
Acupressure bands 56 19 13 10 4 66
Cycle 4
None 35 20 10 8 6 87
Sham bands 44 16 13 4 1 88
Acupressure bands 57 14 6 7 2 82
NA, no data available.
 z the estimated odds ratio (OR) of a lower (i.e. better) score for acupressure than for the control is 
e0.2418 = 1.27 [95% confidence interval (CI) 0.80 to 2.03]
 z the estimated OR of a lower (i.e. better) score for sham acupressure than for the control is 
e0.3354 = 1.40 (95% CI 0.87 to 2.24).
Hence, patients in the acupressure arm are 27% more likely to have less nausea/vomiting than patients 
in the control arm and patients in the sham arm are 40% more likely to have less nausea/vomiting than 
patients in the control arm.
Adjusted fit (age, gender and emetogenic risk)
The snippet of output presented in Table 15 is for an adjusted fit using all of the available data (n = 361).
Table 16 shows the results of the regression analysis assessing variables that affect the primary outcome 
of nausea. It indicates that, irrespective of arm allocation, subjects who were > 50 years old and male 
had a better nausea outcome. Also, the emetogenicity of the drug was a significant factor in the 
nausea outcome.
These data show that:
 z the likelihood ratio test of the proportional odds assumption is non-significant (p = 0.66) meaning 
that there is no good evidence against this assumption
 z the likelihood ratio test for the trial arm effects after adjustment for age group, gender and 
emetogenic risk group is non-significant (p = 0.34)
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TABLE 11 Multinational Association of Supportive Care in Cancer Antiemesis Tool – acute vomiting: numbers of 
participants reporting a score from 0 to 10
Score
0 1–3 4–6 7–9 10 NA
Cycle 1
None 99 10 4 2 2 49
Sham bands 106 12 1 1 1 45
Acupressure bands 110 11 5 1 3 38
Cycle 2
None 97 8 1 4 0 56
Sham bands 94 7 4 1 0 60
Acupressure bands 101 9 2 0 3 53
Cycle 3
None 91 3 1 1 1 69
Sham bands 81 5 1 1 0 60
Acupressure bands 91 8 3 0 0 66
Cycle 4
None 75 4 1 1 0 85
Sham bands 72 6 0 1 0 87
Acupressure bands 86 3 0 1 0 78
NA, no data available.
 z the estimated OR of a lower (i.e. better) score for acupressure than for the control (for identical age 
group, gender and emetogenic risk group) is e0.1689 = 1.18 (95% CI 0.74 to 1.90)
 z the estimated OR of a lower (i.e. better) score for sham acupressure than for the control (for identical 
age group, gender and emetogenic risk group) is e0.3520 = 1.42 (95% CI 0.88 to 2.30).
Hence, considering the three risk factors presented in Table 16 and the adjusted data presented earlier, 
patients in the acupressure arm are 18% more likely to have less nausea/vomiting than patients in the 
control arm and patients in the sham arm are 42% more likely to have less nausea/vomiting than patients 
in the control arm.
It is of interest to consider the impact of adding a trial arm by term interaction effect to the fitted model 
for each of age group, gender and emetogenic risk group in turn. A regression analysis presents the 
findings of this analysis (Table 17).
This indicates that there is evidence to suggest that treatment effects may vary with gender. This merits 
further investigation (see Simple illustration of primary outcome by trial arm and gender).
Adjusted fit (age, gender, emetogenic risk, cycle frequency, anxiety and 
nausea expectation)
There were further values missing for the baseline Hospital Anxiety and Depression Scale anxiety score and 
the pretreatment nausea expectation score. Hence, the snippet of output presented in Table 18 is for an 
adjusted fit using all of the available data (n = 315).
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TABLE 12 Multinational Association of Supportive Care in Cancer Antiemesis Tool – delayed vomiting: numbers of 
participants reporting a score from 0 to 4
Score
0 1 2 3 4 NA
Cycle 1
None 99 9 6 2 3 47
Sham bands 103 7 3 2 2 49
Acupressure bands 108 8 7 2 3 40
Cycle 2
None 94 7 3 0 2 60
Sham bands 98 3 2 1 1 61
Acupressure bands 104 7 3 0 2 52
Cycle 3
None 86 2 2 1 2 73
Sham bands 80 5 2 1 1 77
Acupressure bands 90 6 2 2 1 67
Cycle 4
None 71 2 2 2 3 86
Sham bands 71 3 2 2 0 88
Acupressure bands 80 4 1 1 0 82
NA, no data available.
Mean Rhodes nausea experience (days 0 to 6 of cycle 1)
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FIGURE 3 Primary outcome distribution (n = 361). The intervals are [0,1], (1,2], (2,3], . . . [11,12]. The first and last 
intervals are closed at both ends and intervals in between are open at their lower bound and closed at their upper 
bound.
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FIGURE 4 Box and whisker plot of the primary outcome by trial arm.
TABLE 13 Ordered categories of nausea experience by trial arm: numbers of participants in each range of 
nausea scores
Category Nausea score None Sham bands Acupressure bands
1 0 34 36 41
2 (0, 2) 35 47 38
3 (2, 4) 21 19 28
4 (4, 6) 14 8 11
5 (6, 12) 13 8 8
TABLE 14 Unadjusted fit model for nausea experience
Coefficients Definition Value Standard error t-value
ArmSham (Sham = 1, otherwise = 0) 0.3354 0.2356 1.424
ArmAcupressure (Acu = 1, otherwise = 0) 0.2418 0.2334 1.036
Intercepts Value Standard error t-value
1|2 –1.0138 0.1836 –5.5203
2|3 0.3777 0.1775 2.1281
3|4 1.3821 0.1943 7.1138
4|5 2.2506 0.2343 9.6047
Residual deviance: 1055.186.
Akaike information criterion: 1067.186.
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TABLE 15 Adjusted fit model for age, gender and emetogenic level in relation to nausea experience
Coefficients Value Standard error t-value
ArmSham 0.3520 0.2400 1.4670
ArmAcu 0.1689 0.2368 0.7131
Age51Plus 0.7445 0.2141 3.4766
GenderMale 0.7554 0.2692 2.8060
EmetogenicRiskLow 1.3783 0.4918 2.8025
EmetogenicRiskModerate 0.3369 0.2164 1.5572
Intercepts Value Standard error t-value
1|2 –2.0399 0.2793 –7.3029
2|3 –0.4924 0.2579 –1.9094
3|4 0.5786 0.2627 2.2021
4|5 1.4753 0.2909 5.0720
Residual deviance: 1006.691.
Akaike information criterion: 1026.691.
TABLE 16 Regression analysis: variables influencing the primary outcome (four variables model)
Term df p-value
Arm 2 0.34
Age ≥ 51 years 1 0.0005
Male 1 0.005
Emetogenic risk group 2 0.013
df, degrees of freedom.
TABLE 17 Regression analysis: trial arm by term interaction effect (four variables model)
Interaction term df p-value
Arm × (Age ≥ 51) 2 0.70
Arm × Male 2 0.002
Arm × (Emetogenic risk group) 4 0.88
df, degrees of freedom.
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A regression analysis, presented in Table 19, shows that age > 50 years, male gender and lower 
expectation of nausea are significantly linked with lower levels of nausea. The role of the emetogenicity of 
the chemotherapy in this analysis was borderline non-significant.
These data show that:
 z the likelihood ratio test of the proportional odds assumption is non-significant (p = 0.31), meaning 
that there is no good evidence against this assumption
 z the likelihood ratio test for the trial arm effects after adjustment for age group, gender, emetogenic 
risk group, cycle frequency, anxiety and nausea expectation is non-significant (p = 0.60)
 z the estimated OR of a lower (i.e. better) score for acupressure than for the control (for identical values 
of the other covariates in the model) is e0.1294 = 1.14 (95% CI 0.69 to 1.88)
 z the estimated OR of a lower (i.e. better) score for sham acupressure than for the control (for identical 
values of the other covariates in the model) is e0.2642 = 1.30 (95% CI 0.77 to 2.19).
Hence, considering the risk factors presented in Table 19 and the adjusted data presented earlier in this 
section, patients in the acupressure arm are 14% more likely to have less nausea/vomiting than patients 
in the control arm, and patients in the sham arm are 30% more likely to have less nausea/vomiting than 
patients in the control arm.
It is of interest to consider the impact of adding a trial arm by term interaction effect to the fitted model 
for each of age group, gender, emetogenic risk group, cycle frequency, anxiety and nausea expectation in 
turn. The results of this analysis are presented in Table 20 and show that only gender (with anxiety being a 
borderline non-significant variable) is significantly linked with the primary outcome, once again indicating 
that there is some evidence to suggest that treatment effects may vary with gender. This merits further 
investigation (see Simple illustration of primary outcome by trial arm and gender).
TABLE 18 Adjusted fit model for age, gender, emetogenic level, timing of delivery of chemotherapy and anxiety and 
nausea expectation in relation to nausea experience
Coefficients Value Standard error t-value
ArmSham 0.26417 0.25973 1.0171
ArmAcu 0.12936 0.25220 0.5129
Age51Plus 0.51111 0.22929 2.2291
GenderMale 0.67565 0.32595 2.0729
EmetogenicRiskLow 1.23203 0.56228 2.1911
EmetogenicRiskModerate 0.29651 0.23076 1.2849
TwoWeekly –0.06794 0.41474 –0.1638
Anxiety –0.03628 0.02613 –1.3887
NauseaExpectation –0.15455 0.05046 –3.0627
Intercepts Value Standard error t-value
1|2 –0.8360 0.3876 –2.1567
2|3 0.7305 0.3872 1.8868
3|4 1.8205 0.4011 4.5389
4|5 2.8123 0.4293 6.5504
Residual deviance: 868.2679.
Akaike information criterion: 894.2679.
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Simple illustration of primary outcome by trial arm and gender
The regression analyses above suggest that there may be a trial arm by gender interaction. To illustrate 
this, we may return to the box and whisker plots by trial arm further broken down by gender as shown 
in Figures 5 and 6. Given that we have seen a statistically significant interaction in the ordinal regression 
analyses, there is some justification to repeat the Kruskal–Wallis tests separately within the two gender 
strata. This yields significant results for men (p = 0.04; n = 79) and for women (p = 0.01; n = 282). 
Descriptively, the difference appears to be with the sham arm having a beneficial effect for women but 
a detrimental effect for men. This is a post hoc analysis and should be interpreted with due caution 
especially as there are a limited number of men.
Longitudinal regression analyses of mean Rhodes Index of 
Nausea, Vomiting and Retching nausea experience scores
The mean Rhodes Index of Nausea, Vomiting and Retching nausea experience scores (days 0–6) have 
also been calculated for cycles 2, 3 and 4. Once again, the scores for each cycle have been grouped 
in the same manner as previously to a 5-point ordinal scale. These repeated ordinal data have been 
analysed using an extension of the proportional odds regression model described previously, this time 
fitted using a GEE approach.61 A working autoregressive correlation structure has been assumed, but 
the regression parameters are robust to this assumption. All reported Wald tests have used the robust 
covariance estimates.
TABLE 19 Regression analysis: variables influencing the primary outcome (six variables model)
Interaction term df p-value
Arm 2 0.60
Age ≥ 51 years 1 0.025
Male 1 0.038
Emetogenic risk group 2 0.067
2-weekly CT 1 0.87
Anxiety 1 0.16
Nausea expectation 1 0.002
df, degrees of freedom.
TABLE 20 Regression analysis: trial arm by term interaction effect (six variables model)
Interaction term df p-value
Arm × (Age ≥ 51) 2 0.78
Arm × Male 2 0.023
Arm × (Emetogenic risk group) 4 0.93
Arm × (2-weekly) 2 0.14
Arm × Anxiety 2 0.08
Arm × (Nausea expectation) 2 0.16
df, degrees of freedom.
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Unadjusted fit
First, a trial arm by cycle model was fitted and the interaction term was tested for significance (Wald test 
chi-squared on 6 df, p = 0.25). There being no formal evidence for different treatment effects with cycle, 
the simpler trial arm plus cycle model was fitted as presented in Table 21.
0 2 4 6 8 10 12
Mean Rhodes nausea experience (days 0 to 6 of cycle 1)
Acu
Sham
None
FIGURE 5 Box and whisker plot of the primary outcome by trial arm for men.
0 2 4 6 8 10 12
Mean Rhodes nausea experience (days 0 to 6 of cycle 1)
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Sham
None
FIGURE 6 Box and whisker plot of the primary outcome by trial arm for women.
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 z The likelihood ratio test of the proportional odds assumption is non-significant (p = 0.27), meaning 
that there is no good evidence against this assumption.
 z The estimated correlation parameter (95% CI) is 0.345 (0.001 to 0.997), that is, mild autocorrelation 
with a very wide CI.
 z The Wald test for the trial arm effects on 2 df is of borderline significance (p = 0.07).
 z The estimated OR of a lower (i.e. better) score for acupressure than for the control is e0.4255 = 1.53 
(95% CI 1.12 to 2.09).
 z The estimated OR of a lower (i.e. better) score for sham acupressure than for the control is 
e0.3823 = 1.47 (95% CI 1.06 to 2.02).
 z The GEE approach is valid with an ignorable missing response mechanism (missing completely at 
random). All results should be interpreted with this in mind and sensitivity analyses with respect to 
missing data mechanisms will be performed.
Trial arm effects by gender from adjusted regression analyses
The regression analyses described previously for the cycle 1 nausea primary outcome revealed a trial arm by 
gender interaction. A parallel longitudinal analysis also displayed the same interaction (data not shown). A 
useful summary of the trial arm effects is given in Tables 22 (cycle 1) and 23 (cycle-averaged data). The OR 
terms are the odds of a lower (i.e. better) nausea score for each of categories 1–4 in the 5-point ordinal 
scale described previously.
From these OR estimates and CIs we see that there was a statistically significant benefit for women in the 
sham arm (but not for men for whom the effect was in fact reversed). Both men and women appear to 
have enjoyed a benefit of similar magnitude in the acupressure arm but this is not formally statistically 
significant. The same caveats as mentioned previously apply, that is, this is a post hoc analysis, there are a 
relatively small number of men and assumptions have been made about missing data mechanisms.
Longitudinal analyses of secondary outcomes
Multinational Association of Supportive Care in Cancer Antiemesis Tool: 
acute and delayed nausea
Acute and delayed nausea were both scored from 0 to 10 and were highly skewed with large proportions 
on the 0 extreme. For regression analysis new ordered factors with five levels were created as in Table 24.
TABLE 21 Interaction effects in a model of trial arm by cycle 
Coefficients Estimate Naive standard error Naive z Robust standard error Robust z
Intercept 1|2 –0.9794 0.1399 –6.9980 0.1613 –6.069
Intercept 2|3 0.2440 0.1357 1.7972 0.1567 1.557
Intercept 3|4 1.1257 0.1439 7.8185 0.1628 6.910
Intercept 4|5 1.9900 0.1675 11.8760 0.1876 10.607
Sham 0.3823 0.1603 2.3851 0.1977 1.933
Acu 0.4255 0.1563 2.7225 0.2023 2.103
Cycle2 0.0406 0.1124 0.3609 0.0899 0.451
Cycle3 0.1680 0.1341 1.2530 0.0973 1.725
Cycle4 0.4708 0.1472 3.1984 0.1199 3.925
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The regression analyses followed a similar approach to that employed for nausea experience measured 
using the Rhodes Index of Nausea, Vomiting and Retching scale as described earlier. For both outcomes 
there was no evidence of an arm by cycle interaction but both outcomes exhibited evidence of an 
arm by gender interaction. Tables 25 and 26 show the arm effect estimates for acute and delayed 
nausea respectively.
Multinational Association of Supportive Care in Cancer Antiemesis Tool: 
acute and delayed vomiting
The mean (days 0–6) MAT vomiting experience data were highly skewed. The data were grouped 0, (0,1), 
(1,2), (2,3) and > 3. When analysed with a longitudinal proportional odds model there was no evidence of 
any trial arm effects (p = 0.47, Wald test).
The MAT scale acute vomiting data were recorded as the number of times vomiting occurred in the 
24 hours since chemotherapy. Descriptively there was no difference between the trial arms. The MAT scale 
delayed vomiting data were recorded as the number of days on which vomiting occurred (0–4). When 
analysed with a longitudinal proportional odds model there was no evidence of any trial arm effects 
(p = 0.69, Wald test).
TABLE 22 Odds ratios and CIs for nausea experience in cycle 1
Effect OR estimatea 95% CI
Sham acupressure compared with none (men) 0.35 0.12 to 1.03
Sham acupressure compared with none (women) 2.02 1.19 to 3.42
Acupressure compared with none (men) 1.27 0.40 to 4.08
Acupressure compared with none (women) 1.17 0.70 to 1.95
a From a proportional odds model adjusting for gender, age group and emetogenic risk group.
TABLE 23 Odds ratio and CIs for nausea experience: longitudinal outcomes (i.e. cycle-averaged effects)
Effect OR estimatea 95% CI
Sham acupressure compared with none (men) 0.66 0.29 to 1.48
Sham acupressure compared with none (women) 1.71 1.10 to 2.65
Acupressure compared with none (men) 1.47 0.59 to 3.68
Acupressure compared with none (women) 1.44 0.93 to 2.23
a From a proportional odds model (GEE fit) adjusting for gender, age group, emetogenic risk group and cycle.
TABLE 24 New ordered factors with five levels for regression analysis
Group Score
None 0
Mild 1–3
Moderate 4–6
High 7–9
Severe 10
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TABLE 25 Longitudinal outcomes – cycle-averaged effects for the MAT scale: acute nausea
Effect OR estimatea 95% CI
Sham acupressure compared with none (men) 0.32 0.12 to 0.82
Sham acupressure compared with none (women) 1.62 1.04 to 2.53
Acupressure compared with none (men) 0.63 0.21 to 1.96
Acupressure compared with none (women) 1.27 0.82 to 1.96
a From a proportional odds model (GEE fit) adjusting for gender, age group, emetogenic risk group and cycle.
TABLE 26 Longitudinal outcomes – cycle-averaged effects for the MAT scale: delayed nausea
Effect OR estimatea 95% CI
Sham acupressure compared with none (men) 0.54 0.21 to 1.40
Sham acupressure compared with none (women) 1.74 1.12 to 2.68
Acupressure compared with none (men) 0.99 0.37 to 2.69
Acupressure compared with none (women) 1.49 0.97 to 2.28
a From a proportional odds model (GEE fit) adjusting for gender, age group, emetogenic risk group and cycle.
Longitudinal analyses for nausea and vomiting using post hoc 
dichotomies
In previous analyses these outcomes were mapped to a 5-point ordinal scale and proportional odds 
models were fitted. In each case a test of the proportional odds assumption was made and found to be 
non-significant. Essentially that implies that the odds of a lower score for a variable (notably trial arm) 
does not depend on the particular cut point. Most cases have low scores for nausea and vomiting and it 
is felt that a simple dichotomy may give an adequate simpler description (Tables 27–32 provide data for 
the Rhodes Index of Nausea, Vomiting and Retching and the MAT scale). Longitudinal binomial models 
were fitted (cycle + arm using the GEE approach) with a general working correlation structure and a Wald 
test employed using the robust covariance estimates to assess the trial arm effects. The reason for the 
dichotomies stated above is that the models for ordinal data typically consider the cumulative logits (CL), 
that is, the log-odds of a lower score. With the five categories used for the nausea outcome we consider 
four such CLs evaluated at the category upper limits:
CL(y) = log[Prob(Y ≤ y)/Prob(Y > y)], y = 0, 2, 4, 6 (2)
In a regression context we aim to see how covariates affect these CLs. In an unconstrained model there 
would be a term for each covariate for each of the four response categories. Nausea experience and 
vomiting experience are each scored from 0 to 12, whereas MAT is scored from 0 to 10. All of these 
distributions are markedly skewed, with those for vomiting being even more skewed than those for 
nausea. Five categories were selected for each but the definitions of these were permitted to vary from 
variable to variable. As the proportional odds assumption was not violated for each variable, the results 
should not be too sensitive to the particular dichotomy used.
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TABLE 27 Frequency of nausea per trial arm: Rhodes Index of Nausea, Vomiting and Retching nausea experience 
(days 0–6) = 0–2 inclusive
Cycle 1, n/N (%) Cycle 2, n/N (%) Cycle 3, n/N (%) Cycle 4, n/N (%)
None 69/117 (59) 61/109 (56) 55/96 (57) 50/81 (62)
Sham bands 83/118 (70) 77/105 (73) 64/88 (73) 52/74 (70)
Acupressure bands 79/126 (63) 72/114 (63) 72/103 (70) 70/90 (78)
The Wald test for the arm effects gave p = 0.08 with the ORs of the lower score being estimated at 1.62 
for sham acupressure and 1.46 for acupressure compared with no bands.
TABLE 28 Frequency of vomiting per trial arm: Rhodes Index of Nausea, Vomiting and Retching vomiting experience 
(days 0–6) = 0–1 inclusive
Cycle 1, n/N (%) Cycle 2, n/N (%) Cycle 3, n/N (%) Cycle 4, n/N (%)
None 100/118 (85) 94/108 (87) 88/96 (92) 71/81 (88)
Sham bands 107/119 (90) 95/105 (90) 83/88 (94) 73/77 (95)
Acupressure bands 109/126 (87) 106/114 (93) 96/103 (93) 85/90 (94)
The Wald test for the arm effects gave p = 0.19 with the ORs of the lower score being estimated at 1.74 
for sham acupressure and 1.46 for acupressure compared with no bands.
TABLE 29 Multinational Association of Supportive Care in Cancer Antiemesis Tool: acute nausea frequency per trial 
arm = 0–3 inclusive
Cycle 1, n/N (%) Cycle 2, n/N (%) Cycle 3, n/N (%) Cycle 4, n/N (%)
None 83/117 (71) 84/110 (76) 76/96 (79) 61/81 (75)
Sham bands 98/120 (82) 92/106 (87) 74/89 (83) 65/79 (82)
Acupressure bands 101/130 (78) 93/116 (80) 80/102 (78) 73/88 (83)
The Wald test for the arm effects gave p = 0.18 with the ORs of the lower score being estimated at 1.60 
for sham acupressure and 1.29 for acupressure compared with no bands.
TABLE 30 Multinational Association of Supportive Care in Cancer Antiemesis Tool: delayed nausea frequency per trial 
arm = 0–3 inclusive
Cycle 1, n/N (%) Cycle 2, n/N (%) Cycle 3, n/N (%) Cycle 4, n/N (%)
None 73/118 (62) 66/105 (63) 65/93 (70) 55/79 (70)
Sham bands 86/116 (74) 78/105 (74) 68/89 (76) 60/78 (77)
Acupressure bands 88/128 (69) 85/116 (73) 75/102 (74) 71/86 (83)
The Wald test for the arm effects gave p = 0.13 with the ORs of the lower score being estimated at 1.51 
for sham acupressure and 1.43 for acupressure compared with no bands.
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TABLE 31 Multinational Association of Supportive Care in Cancer Antiemesis Tool: acute vomiting frequency per 
trial arm = 0
Cycle 1, n/N (%) Cycle 2, n/N (%) Cycle 3, n/N (%) Cycle 4, n/N (%)
None 99/117 (85) 97/110 (88) 91/97 (94) 75/81 (93)
Sham bands 106/121 (88) 94/106 (89) 81/88 (92) 72/79 (91)
Acupressure bands 110/130 (85) 101/115 (88) 91/102 (89) 86/90 (96)
The Wald test for the arm effects gave p = 0.98, with the ORs of the lower score being estimated at 1.05 
for sham acupressure and 1.00 for acupressure compared with no bands.
TABLE 32 Multinational Association of Supportive Care in Cancer Antiemesis Tool: delayed vomiting frequency per 
trial arm = 0
Cycle 1, n/N (%) Cycle 2, n/N (%) Cycle 3, n/N (%) Cycle 4, n/N (%)
None 99/119 (83) 94/106 (89) 86/93 (92) 71/80 (89)
Sham bands 103/117 (88) 98/105 (93) 80/89 (90) 71/78 (91)
Acupressure bands 108/128 (84) 104/116 (90) 90/101 (89) 80/86 (93)
The Wald test for the arm effects gave p = 0.69, with the ORs of the lower score being estimated at 1.28 
for sham acupressure and 1.05 for acupressure compared with no bands.
Results for the Hospital Anxiety and Depression Scale and the 
Functional Assessment of Cancer Therapy – General scale
These two scales were assessed at baseline and at cycles 1–4. Longitudinal linear models were fitted 
(GEE approach using unstructured covariance matrices) to the cycles 1–4 data using the relevant baseline 
variable as a covariate along with factors representing cycle and arm. There was no evidence of any trial 
arm effects on mean values, as can be seen from Table 33.
Scale reliability
A descriptive measure of scale reliability (Cronbach’s alpha) has been calculated at baseline. FACT scales 
may be calculated with four or more completed items; however, for Cronbach’s alpha analysis all items 
must be completed. As can be seen in Table 34, all scales used in the study had very good reliability values.
Wristband audit
In total, 35 ‘wrist pairs’ were observed during the months August–November 2010 in the outpatient 
departments at four trial sites (Royal Oldham Hospital, Macclesfield District General Hospital, Liverpool 
Royal Hospital and Clatterbridge Centre for Oncology).
The vast majority of observations indicated that both wristbands (i.e. on both left and right wrists) 
were being worn correctly. In two instances a patient was observed to be wearing only one of a pair 
of wristbands on arrival at the outpatient department, with one patient having a swollen left arm and 
the other patient having removed one wristband in advance of chemotherapy administration with the 
intention of wearing the wristband after the chemotherapy had been given. Eight patients were not 
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wearing their wristbands, with one patient having swollen hands and the remaining seven patients stating 
that they intended to wear their wristbands after chemotherapy had been administered. Three patients 
who were using spare wristbands offered to them by the research nurse correctly demonstrated their use.
Only four of the 68 wristbands observed (i.e. for left and right wrists) were positioned incorrectly. Three 
of these were worn incorrectly on the right wrist and one was worn incorrectly on the left wrist. Figure 7 
shows the distribution of wristband observations.
TABLE 33 Analysis of Hospital Anxiety and Depression Scale and FACT-G scale data by trial arm
Variable Scale
Cycle × arm p-value 
(model 1)a
Arm p-value  
(model 2)b Sham bandsc Acupressure bandsc
Anxiety 0–21 0.34 0.48 0.11 (0.38) –0.35 (0.37)
Depression 0–21 0.15 0.40 0.02 (0.37) 0.45 (0.36)
PWB 0–28 0.07 0.71 0.48 (0.67) 0.02 (0.66)
SFWB 0–28 0.37 0.82 –0.13 (0.46) –0.24 (0.39)
EWB 0–24 0.80 0.77 0.05 (0.39) 0.26 (0.38)
FWB 0–28 0.39 0.86 0.11 (0.68) 0.35 (0.65)
FACT-G 0–108 0.71 0.81 0.92 (1.67) –0.06 (1.62)
EWB, emotional well-being; FWB, functional well-being; PWB, physical well-being; SFWB, social well-being. 
a  Wald test from a y.baseline + cycle × arm model.
b  Wald test from a y.baseline + cycle + arm model.
c The estimated difference in means from the ‘None’ group from model (2) with standard errors in parentheses. These 
effects are very small and non-significant.
TABLE 34 Cronbach’s alpha reliability of the scales used in the trial for the current sample
Scale
Number of 
items Time point
n 
complete
Cronbach’s 
alpha
Rhodes Index of Nausea, Vomiting 
and Retching nausea experience
3 Cycle 1 day 1 (day following CT) 356 0.915
Rhodes Index of Nausea, Vomiting 
and Retching vomiting experience
3 Cycle 1 day 1 (day following CT) 358 0.883
Hospital Anxiety and Depression 
Scale: anxiety
7 Baseline 414 0.884
Hospital Anxiety and Depression 
Scale: depression
7 Baseline 420 0.824
FACT-G: PWB 7 Baseline 381 0.742
FACT-G: SFWB 7 Baseline 215 0.777
FACT-G: SFWB 6a Baseline 377 0.844
FACT-G: EWB 6 Baseline 397 0.790
FACT-G: FWB 7 Baseline 354 0.863
FACT-G from four subscales 4 Baseline 363 0.743
CT, chemotherapy; EWB, emotional well-being; FWB, functional well-being; PWB, physical well-being; SFWB, social well-
being. 
a Omitting sex-life question.
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The condition of the wristbands was also noted by the research nurses for a total of 25 pairs. Six 
wristbands were in poor condition: two pairs of wristbands (one pair being worn for the fourth cycle 
of chemotherapy and one pair being worn for the second cycle of chemotherapy) were in generally 
poor condition and one pair of wristbands being worn for the third cycle of chemotherapy had loose 
acupressure buttons on both bands. All of these bands were replaced. In total, 22 pairs of wristbands were 
recorded as being in good condition.
Side effects from wearing the wristbands
A small number of patients in the trial reported problems with wearing their wristbands:
 z One patient stated that the wristbands felt ‘too tight’ – this patient was offered larger wristbands and 
was advised not to continue wearing the bands if the large bands also felt tight.
 z Six patients reported that their hands and/or arms had become swollen after receiving chemotherapy – 
two of these patients wanted to try wearing larger bands but all patients were advised not to wear the 
bands while the swelling persisted.
 z One patient reported a painful arm after receiving chemotherapy, which made wearing the wristband 
uncomfortable – this patient was advised not to wear the wristband on the painful arm until the pain 
had subsided.
 z One patient reported some swelling of their arms after wearing the wristbands – this patient was 
advised not to wear the wristbands but was also advised to attempt to wear the wristbands at a later 
stage once the swelling had subsided but to discontinue using the wristbands if swelling occurred on 
the second attempt to wear the bands.
 z Two patients stated that they had experienced some ‘irritation’ from wearing the wristbands – both 
patients were advised to discontinue wearing them.
 z Two patients stated that they had experienced some ‘sensitivity’ to the wristbands – both patients 
were advised to discontinue wearing them.
 z One patient reported experiencing ‘intolerance’ to wearing the wristbands – the patient was advised 
to discontinue wearing them.
 z One patient reported that the wristbands felt ‘uncomfortable’ – this patient was offered a pair of 
large-sized wristbands but these still felt ‘uncomfortable’ and so the patient was advised to stop 
wearing them.
In all of the cases above, patients were reminded to complete their wristband compliance 
questionnaires accordingly.
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FIGURE 7 Wristband observations during the audit (n = 70).
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Chapter 5 Health economics data
Context of the data
Aim and perspective
The aim was to assess the cost-effectiveness of self-acupressure using wristbands in addition to standard 
care compared with standard care with sham acupressure wristbands and standard care alone in 
the management of chemotherapy-induced (acute and delayed) nausea. The study adopted a NHS 
perspective in relation to cost evaluation to inform health policy relating to the use of acupressure bands 
in chemotherapy patients. A societal perspective for costs was adopted for sensitivity analysis. Reporting 
made reference to economic evaluation good practice.62
Time frame
Costs and benefits were calculated for the study period (four cycles of chemotherapy) only, which was 
21 days. As the trial has a time frame of less than a year neither costs nor benefits were discounted.
Resource use and costs
Resource-use data collected in the trial and unit costs are presented in Appendix 11. These include number 
of visits to the GP, practice nurse, pharmacist, health visitor and specialist nurse, number of consultations 
during hospital stays and medication use.
Data were collected prospectively and retrospectively using multiple sources including patient records 
and patient self-reported questionnaires. The questionnaires report health service utilisation subsequent 
to and as a result of chemotherapy-induced nausea and vomiting. Direct medical costs incurred by the 
NHS and social services are defined as the costs of prophylactic or rescue antiemetic medications, drug 
administration devices, staff time associated with preparing and administering medication and tending to 
patients with chemotherapy-induced nausea and vomiting, hospitalisations due to chemotherapy-induced 
nausea and vomiting and hospital outpatient or GP visits due to chemotherapy-induced nausea and 
vomiting. The analysis did not include costs for chemotherapy agents, preplanned visits or hospitalisations 
for the purpose of chemotherapy administration and diagnostic and laboratory tests, and other patient 
management costs not directly related to chemotherapy-induced nausea and vomiting. The resource-use 
questionnaire completed by patients asked them to record only health service resource usage that was as a 
result of chemotherapy-related nausea or vomiting.
Appendix 12 lists each of the drugs that were prescribed within the study. The Commercial Medicines Unit 
(CMU) electronic Market Information Tool (eMIT)63 was used to cost the drugs; however, when drugs were 
not listed on eMIT, costs were taken from the British National Formulary (BNF).64 Expert opinion was elicited 
on the standard practice for antiemetics during chemotherapy and the standard dose for each of the 
drugs. As Zofran is the brand name of ondansetron we used this (higher) cost only when it was stated that 
Zofran was prescribed. All other ondansetron prescriptions were costed at the eMIT price for ondansetron.
The total cost of each arm of the trial is calculated by combining the resource use and unit cost data along 
with the cost of drugs and the price of the acupressure band. There were a number of assumptions that 
were made when analysing the cost data. The cost of the sham acupressure band was assumed to be 
the same as the cost of the acupressure band. If the patient did not fill in the resource-use form (left it 
blank), we assumed that the data were missing. Hospitalisations that led to one face-to-face contact were 
assumed to represent a short stay and those with more than one face-to-face contact were assumed to 
represent a long stay.
Assumptions relating to the reported medication use are indicated in the following section.
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Assumptions made on antiemetic use
 z All patients received a standard care:
 | moderate/high emetogenic risk: domperidone 20 mg four times a day for 7 days; ondansetron 
8 mg intravenously on day of chemotherapy, 8 mg orally twice a day for 3 days; dexamethasone 
8 mg intravenously on day of chemotherapy, 8 mg orally for 1 day, 4 mg for 1 day, 2 mg for 1 day.
 | low emetogenic risk: domperidone 20 mg four times a day for 7 days.
 z Prolonged course = double the number of days on the antiemetic.
 z If form stated ‘as required’ = 7 days on stated drug.
 z Assumed that all medication was tablet form unless stated.
 z When medication details were not provided (only ‘antiemetics given’ stated), assumed standard care.
 z When doses were not recorded expert opinion was used on average normal dose of each drug.
 z If not stated assume that next cycle is the same as the previous cycle.
Societal costs
Costs from the societal perspective were calculated by combining productivity loss and loss of earnings 
due to work absence and out-of-pocket expenses incurred as a result of chemotherapy-induced nausea 
and vomiting. For productivity loss we employed a human capital approach using the gross median weekly 
pay rate (£499) for full-time employees from the 2010 Annual Survey of Hours and Earnings65 and divided 
this by five. This was then reduced to 80% to represent the fact that absence from work will not lead to a 
proportionate loss of productivity,66 giving a daily productivity loss cost of £79.84. As there were a lot of 
missing data it was assumed that these reflected zero costs incurred.
Outcome measurement and valuation
Participant health-related quality of life was assessed using the European Quality of Life-5 Dimensions 
(EQ-5D),67 which was included along with the patient resource-use questionnaires. Differences between 
the randomised groups at follow-up with respect to EQ-5D scores were investigated using non-parametric 
Mann–Whitney U-tests as the data were not normally distributed. Change scores over time were evaluated 
using independent t-tests.
Participant responses to the EQ-5D questionnaire were converted to health-state utility values using the 
UK tariff values68 and an area under the curve approach. These values were then multiplied by duration 
(21 days) in each health state and divided by 365 to estimate QALYs. QALYs represent a quality-weighted 
survival value in which 1 QALY is the equivalent of 1 year of full health. Average QALYs between 
adjacent time points were calculated to generate smoothed estimates between time points. QALYs were 
calculated as:
Total QALYs = ((EQ5D_T1 × 21) + (EQ5D_T2m × 21)/2) + ((EQ5D_T2m × 21)  
+ (EQ5D_T3m × 21)/2) + ((EQ5D_T3m × 21) + (EQ5D_T4m × 21)/2)  
+ ((EQ5D_T4m × 21) + (EQ5D_T5m × 21)/2))/365 (3)
where T1, T2m, T3m, T4m and T5m are time points of assessment in the trial, that is, baseline and end of 
cycles 1, 2, 3 and 4 respectively.
Missing data
Respondents who fail to complete individual items of the EQ-5D are not allocated a utility index score.
The last observation carried forward (LOCF) method was employed to deal with missing time point data. 
In this trial there were four cycles of chemotherapy after the baseline observation. If a patient dropped out 
of the study after the third week, this value was then ‘carried forward’ and assumed to be the score for 
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the fourth cycle missing data point. Similarly, if a patient dropped out after baseline this value was carried 
forward to the first cycle of chemotherapy. Scores were carried forward to one consecutive time point only. 
Patients in whom more than one consecutive score was missing were omitted from the analyses. Scores 
were not carried backwards – that is, those without baseline scores did not have their first follow-up score 
carried backwards. The advantage of the LOCF approach is that it minimises the number of subjects who 
are eliminated from the analysis and it allows the analysis to examine the trends over time, rather than 
focusing simply on the end point. Assuming that scores are expected to improve over time, LOCF may be a 
conservative way of dealing with missing data. A full case analysis was conducted in the sensitivity analyses 
in which participants were excluded if they had missing scores from any time point.
We used the same method for missing resource-use data, carrying forward the last observation only once 
if there were missing data for the next time point. Patients were omitted from the analyses if they had 
more than one missing time point.
Economic evaluation
Descriptive statistics of costs and EQ-5D scores were calculated by subgroup. Parametric tests (Student’s 
t-tests and ANOVA tests) and non-parametric tests (Wilcoxon signed-rank tests, Mann–Whitney tests 
and Kruskal–Wallis ANOVA tests) were conducted to evaluate differences in individual characteristics and 
health-related quality-of-life scores between groups. Mann–Whitney U-tests were used to evaluate the 
significance of differences in costs between groups as this test is less likely to be influenced by outliers. For 
the economic evaluation only costs of patients who had a QALY value were included.
The outcome of the cost-effectiveness analysis was an incremental cost per QALY.61,69 We present 
incremental cost-effectiveness ratios (ICERs)61,69 representing the ratios of the incremental cost and 
incremental benefits (QALYs) between acupressure and sham acupressure, between acupressure and 
standard care and between sham acupressure and standard care. The ICER represents the additional cost 
per one unit of outcome gained, in this case per QALY gained for each intervention compared with its next 
best alternative. As a guideline rule, the National Institute for Health and Clinical Excellence (NICE) accepts 
as cost-effective those interventions with an ICER of < £20,000 per QALY. NICE states that, in general, if 
a treatment costs > £30,000 per QALY it would not be considered cost-effective. We also present cost-
effectiveness plane scatter plots illustrating the uncertainty surrounding the cost-effectiveness estimates.
The cost-effectiveness planes were derived using bootstrapping with replacement. This stochastic 
uncertainty analysis involved running 10,000 bootstrapped estimates of the incremental costs and QALYs. 
The bootstrap approach is a non-parametric method that treats the original sample as though it were the 
population and draws multiple random samples from the original sample. Cost-effectiveness acceptability 
curves were also generated to illustrate the probability that each treatment would be cost-effective given a 
range of acceptable threshold values.70
Sensitivity analyses were carried out to account for uncertainty in the cost and EQ-5D values. We 
performed the sensitivity analysis by adding and subtracting 20% of the costs and assessing the 
subsequent impact on the ICERs. The value of 20% is essentially arbitrary but it was considered likely to 
represent any uncertainty that might exist in parameter values. We performed a sensitivity analysis on the 
QALYs by conducting a full-case analysis on EQ-5D scores. In contrast to the LOCF, no missing data are 
imputed and patients with any missing data are omitted from the analyses. Sensitivity analyses were also 
carried out based on using an average group cost for those outliers with high costs and by adopting a 
societal perspective for costs, including productivity losses and lost earnings.
Net benefit values71 were generated to enable more traditional analysis of therapy efficacy. Net benefit is 
a composite representation of cost-effectiveness and willingness to pay that is derived by rearranging the 
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ICER calculation and incorporating the willingness-to-pay threshold value (in this case the £20,000 per 
incremental QALY threshold of NICE). Net monetary benefit (NMB) is derived for each patient as:
NMB = (20,000 × QALYs) – costs (4)
The decision rule becomes to adopt an intervention if the NMB > 0. Because values are transformed from 
ratio to linear we can subsequently employ standard regression models on the data. Net benefit regression 
allows us to control for covariates and baseline between-group differences.72 We applied the variables used 
for the primary end point regression analyses to NMB data with treatment arm included as an independent 
variable. Univariate ANOVA and linear regression models were generated.
Results
Data from 450 patients (157 acupressure, 146 standard care, 147 sham acupressure) were included in the 
base-case analysis.
Resource use and costs
There was very little reported resource use within the trial; thus, caution should be exercised in interpreting 
the results as a small number of high-resource-use consumers or a few instances of high-cost resource 
use may be unduly influencing the overall results. Table 35 shows the number of times each of the health 
service resources was used by trial arm. The acupressure group used the fewest resources and the standard 
care group used the most.
In terms of the total NHS resource-use cost, the acupressure group used the least number of resources 
and also had the lowest cost. Mean total drug costs (including antiemetics and other drugs prescribed 
for chemotherapy-induced nausea and vomiting and antiemetic use outside of the routine pathway 
in each arm of the trial) for the groups were £37.07 (SD £101.72) for the acupressure group, £51.66 
(SD £150.02) for the standard care group and £24.03 (SD £18.70) for the sham acupressure group. Mean 
total costs (drug costs plus all other NHS costs plus band costs) for the acupressure group were lower than 
those for the standard care group or the sham acupressure group (Table 36). ‘All other NHS costs’ include 
the resource use from Table 35. The NHS costs for the sham group appear higher than those for the other 
groups and this seems to be driven by a higher number of district nurse visits and a few patients in the 
TABLE 35 Resource use by the trial participants
Services Acupressure Standard care Sham acupressure
GP surgery visit 5 6 5
GP home visit 3 4 3
District nurse 4 11 17
Contact with oncology hotline for advice 6 11 9
Contact with hospital oncology nurse clinician for advice 9 9 6
Contact with hospital oncology clinic for advice 5 8 7
Hospital inpatient stay 10 14 9
Hospital A&E department 3 1 2
Hospital general outpatient clinic 1 0 2
Other services 3 1 1
Total instances of resource use 49 65 61
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sham arm of the trial having longer inpatient stays. There were no significant differences in costs between 
any of the treatment arms according to the t-tests; this was true for the whole sample as well as for the 
subsample who also had QALY data. Mean values were distorted by a small number of high-cost outlying 
patients leading to high levels of uncertainty around the mean cost estimates. Median total costs were 
£30.92, £22.72 and £30.92 for the acupressure, standard care and sham acupressure groups respectively. 
Mann–Whitney tests indicated that the standard care group had significantly lower total costs than the 
acupressure and sham acupressure groups (both p < 0.001); there was no significant difference in costs 
between the acupressure and sham acupressure groups (p = 0.585). No adjustments for multiple testing 
were considered necessary. Figure 8 shows the cost distribution for the standard care group and illustrates 
the presence of a small number of high-cost outliers. A similar pattern was observed for the other two 
treatment arms.
Table 37 includes costs from the societal perspective. Lost earnings and productivity losses to employers 
through sickness absence appeared higher in the standard care group than in either of the band groups. 
Overall societal costs are similar for the band groups and significantly higher (over double) for the standard 
care group. However, as with the health-care costs, this result is partly driven by a small number of high-
cost outlying individuals, making robust conclusions difficult.
Utility data
Tables 38 and 39 show the numbers of valid and missing EQ-5D questionnaires for each cycle between 
the three arms of the study when no scores are imputed and when values are imputed respectively. Mean 
EQ-5D scores are included for each cycle. Both the acupressure and sham acupressure groups showed 
a slight increase in EQ-5D from baseline to cycle 4 of chemotherapy, whereas the standard care group 
showed a slight decrease. In general, the results indicate small fluctuations in utility values throughout 
the trial period and four chemotherapy cycles, making it difficult to draw conclusions about the impact 
of chemotherapy-induced nausea and vomiting and its treatments on generic health-related quality of 
life. All of the observed changes were below the minimally important difference for the EQ-5D (which 
is estimated to range from 0.1 to 0.1273). Table 40 provides the mean EQ-5D change scores between 
baseline and the follow-up points for the LOCF analysis; these were the values employed in the QALY 
TABLE 36 Costs per arm of the trial
Acupressure (£),  
mean (SD)
Standard care (£),  
mean (SD)
Sham acupressure (£), 
mean (SD)
n 72 62 60
Drug cost – cycle 1 5.47 (1.40) 5.60 (0.65) 5.17 (1.55)
Drug cost – cycle 2 11.71 (36.35) 15.36 (50.43) 5.15 (1.55)
Drug cost – cycle 3 9.92 (33.34) 15.39 (49.77) 6.86 (8.86)
Drug cost – cycle 4 9.96 (33.34) 15.31 (49.80) 6.86 (8.86)
Total drug cost 37.07 (101.72) 51.66 (150.02) 24.03 (18.70)
All other NHS costs – baseline 2.92 (17.56) 0.05 (0.0) 17.29 (124.90)
All other NHS costs – cycle 1 8.52 (34.91) 21.73 (76.90) 9.35 (38.74)
All other NHS costs – cycle 2 9.78 (44.44) 9.18 (44.48) 13.27 (86.59)
All other NHS costs – cycle 3 4.17 (25.80) 16.06 (73.89) 52.13 (303.28)
All other NHS costs – cycle 4 0.0 (0.0) 12.50 (80.47) 37.66 (283.54)
All other NHS costs total 25.39 (81.07) 59.52 (171.78) 129.69 (604.28)
Band cost 8.20 (0.00) 0.00 (0.00) 8.20 (0.00)
Total cost 70.66 (129.75) 111.18 (262.68) 161.92 (604.57)
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calculations. Independent sample t-tests indicated that the changes in EQ-5D score over time were not 
statistically significant.
Statistical tests indicated that there were no significant differences between EQ-5D scores at baseline 
for the three treatment arms. This being the case, baseline adjustments were not required. At baseline 
10.0% (7/70) of the missing EQ-5D values were excluded as a result of one missing response on the 
questionnaire; 3.6% (5/140) of the missing values in cycle 1 were due to missing one response, 1.6% 
(3/192) in cycle 2 were missing one response, 0.9% (2/229) in cycle 3 were missing one response and 
0.3% (1/313) in cycle 4 were missing one response.
FIGURE 8 Total cost distribution for the standard care group.
TABLE 37 Societal costs
Acupressure (£),  
mean (SD)
Standard care (£),  
mean (SD)
Sham acupressure (£), 
mean (SD)
n 72 62 60
Total days out of work 1.18 (6.77) 2.82 (9.89) 0.75 (3.45)
Total lost earnings 54.17 (391.44) 241.42 (1068.43) 31.50 (244.00)
Total expenditure 0.18 (1.15) 0.10 (0.53) 0.00 (0.00)
Social cost – baseline 0.00 (0.00) 19.82 (104.46) 0.00 (0.00)
Social cost – cycle 1 48.95 (255.68) 226.73 (922.55) 19.89 (101.05)
Social cost – cycle 2 52.70 (329.40) 97.17 (347.41) 25.21 (112.07)
Social cost – cycle 3 46.95 (374.77) 69.77 (295.67) 27.80 (159.23)
Social cost – cycle 4 0.00 (0.00) 53.37 (286.99) 18.48 (143.18)
Total social cost 148.60 (925.90) 466.87 (1490.27) 91.38 (472.80)
Total societal costs (social 
cost + health-care costs)
219.26 (983.56) 578.00 (1557.79) 253.30 (760.40)
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TABLE 38 Mean EQ-5D scores: full-case scenario
Time point Acupressure Standard care Sham acupressure
EQ-5D baseline Mean (SD) EQ-5D score 0.764 (0.226) 0.775 (0.210) 0.774 (0.246)
n valid (missing) 133 (24) 126 (20) 121 (26)
EQ-5D cycle 1 Mean (SD) EQ-5D score 0.778 (0.215) 0.784 (0.244) 0.788 (0.254)
n valid (missing) 110 (47) 101 (45) 99 (48)
EQ-5D cycle 2 Mean (SD) EQ-5D score 0.788 (0.190) 0.764 (0.253) 0.799 (0.209)
n valid (missing) 93 (64) 89 (57) 76 (71)
EQ-5D cycle 3 Mean (SD) EQ-5D score 0.732 (0.334) 0.748 (0.237) 0.806 (0.249)
n valid (missing) 79 (78) 72 (74) 70 (77)
EQ-5D cycle 4 Mean (SD) EQ-5D score 0.806 (0.176) 0.752 (0.255) 0.820 (0.266)
n valid (missing) 53 (104) 40 (106) 44 (103)
TABLE 39 Mean EQ-5D scores: LOCF imputed values
Time point Acupressure Standard care Sham acupressure
EQ-5D 
baseline
Mean (SD) EQ-5D score 0.764 (0.226) 0.775 (0.210) 0.774 (0.246)
n valid (missing) 133 (24) 126 (20) 121 (26)
EQ-5D cycle 1 Mean (SD) EQ-5D score 0.748 (0.244) 0.765 (0.244) 0.785 (0.265)
n valid (missing) 148 (9) 141 (5) 138 (9)
EQ-5D cycle 2 Mean (SD) EQ-5D score 0.776 (0.217) 0.763 (0.252) 0.779 (0.255)
n valid (missing) 111 (46) 103 (43) 104 (43)
EQ-5D cycle 3 Mean (SD) EQ-5D score 0.735 (0.314) 0.746 (0.249) 0.797 (0.258)
n valid (missing) 96 (61) 92 (54) 77 (70)
EQ-5D cycle 4 Mean(SD) 0.763 (0.291) 0.749 (0.245) 0.806 (0.246)
n valid (missing) 81 (76) 73 (73) 71 (76)
TABLE 40 Mean EQ-5D change between baseline and follow-up points for the three arms of the trial
Time point Acupressurea Standard carea Sham acupressurea
Baseline to cycle 1 Mean –0.0086 –0.0113 0.0209
n 133 126 121
Baseline to cycle 2 Mean –0.0186 –0.0503 0.0170
n 96 88 86
Baseline to cycle 3 Mean –0.0639 –0.0637 –0.0144
n 85 79 66
Baseline to cycle 4 Mean –0.0401 –0.0649 0.0050
n 74 63 60
a A negative value is a deterioration in quality of life.
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Economic evaluation results regarding quality-adjusted life-year gains
Table 41 shows the total costs and QALY gains for each of the three treatment arms. Differences in QALY 
gains between groups were minimal and suggest only negligible health benefits of acupressure over 
standard care. The sham acupressure group had the highest QALY gains over the trial period with the 
standard care group having the lowest. The mean total cost was highest for the sham acupressure group 
and lowest for the acupressure group. The high SDs for the cost estimates indicate the presence of a few 
outlying individuals who incurred significant health service costs.
Table 42 provides the cost-effectiveness results, showing the incremental costs and benefits as well as 
the ICERs for each arm of the trial. Interpretation should be tempered by considering the high level of 
uncertainty surrounding the cost estimates and the negligible between-group differences observed in 
QALY gains. The standard care group was dominated by acupressure as it had higher costs and lower 
QALY gains. The results suggest that acupressure might be cost saving compared with standard care alone. 
The acupressure group had lower costs than the sham acupressure group; however, the sham group had 
higher, albeit negligible, QALY gains.
Table 43 shows the sensitivity analyses that were carried out as well as the results from the non-parametric 
bootstrapping. The analysis adding 20% to the costs supports the base-case analysis as acupressure still 
dominates the standard care group. Subgroup analyses by emetogenic risk group were not possible as a 
very small proportion of patients was rated as high or low emetogenic risk and a large majority was rated 
as moderate.
Including only patients who had completed EQ-5D scores at every time point did not significantly change 
the ICER. The mean cost and QALY gain estimates from the bootstrapping yield similar ICER results to those 
of the deterministic base-case scenario. Acupressure still dominates standard care only and is cheaper but 
marginally less effective than sham acupressure. Excluding cost outliers or including societal costs does not 
alter the outcome of the key comparisons.
Figures 9 and 10 are cost-effectiveness planes for acupressure compared with standard care and 
acupressure compared with sham acupressure respectively. For acupressure compared with standard care 
(see Figure 9), the 1000 sample estimates are spread mainly in the south-east and south-west quadrants, 
suggesting that acupressure is likely to be cost saving. A high proportion of iteration results are in the 
south-east quadrant suggesting that acupressure is also likely to lead to a higher quality of life; however, 
QALY gains are minimal. For acupressure compared with sham acupressure (see Figure 10), most of the 
TABLE 41 Total costs and QALY gains by treatment arm
Acupressure,  
mean (SD)
Standard care,  
mean (SD)
Sham acupressure,  
mean (SD)
n 72 62 60
Total QALY gain 0.270 (0.062) 0.265 (0.072) 0.283 (0.058)
Total cost (£) 70.66 (129.75) 111.13 (262.68) 161.92 (604.57)
TABLE 42 Cost-effectiveness results
Analysis Incremental cost (£) Incremental QALY gain ICER (£)
Acupressure vs standard care –40.47 0.005 –7494.44 (acupressure 
dominates)
Acupressure vs sham acupressure –91.26 –0.012 7359.68
Sham acupressure vs standard care 50.79 0.018 2853.37
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sample iterations lie in the south-west quadrant, suggesting that acupressure is less effective (leads to 
reduced quality of life) than sham acupressure but leads to cost savings.
Figures 11 and 12 are the cost-effectiveness acceptability curves showing the probability that each 
treatment is a cost-effective choice given a range of cost-effectiveness willingness-to-pay thresholds. 
Figure 11 compares standard care with acupressure. Using the NICE threshold of £20,000 the probability 
that acupressure is cost-effective is 0.70 compared with standard care. Figure 12 compares all three 
treatments. At the NICE threshold of £20,000, sham acupressure appears more likely to be the cost-
effective option (p = 0.71) than acupressure (p = 0.20). Only at low willingness-to-pay thresholds 
(< £7000) does acupressure become the most likely option to be cost-effective. However, considering the 
negligible QALY gains observed in the study, the low levels of resource use, the low median health-care 
costs and the leverage of a few high-cost outliers, any results must be treated with caution. It is difficult to 
make robust claims about the comparative cost-effectiveness of any of the therapy arms.
TABLE 43 Sensitivity analyses
Analysis
Incremental 
cost (£)
Incremental 
QALY gain ICER (£)
+20% of costs
Acupressure vs standard care –48.56 0.005 –8993.33 (acupressure dominates)
Acupressure vs sham acupressure –109.51 –0.012 8831.61
Sham acupressure vs standard care 60.95 0.018 3424.04
–20% of costs
Acupressure vs standard care –32.38 0.005 –5995.56 (acupressure dominates)
Acupressure vs sham acupressure –73.01 –0.012 5887.74
Sham acupressure vs standard care 40.63 0.018 2282.70
EQ-5D full-case scenario
Acupressure vs standard care –111.51 0.009 –12,319.31 (acupressure dominates)
Acupressure vs sham acupressure –153.92 –0.018 8538.87
Sham acupressure vs standard care 42.41 0.027 1566.25
Excluding cost outliers
Acupressure vs standard care –7.58 0.005 –1403.70
Acupressure vs sham acupressure –9.68 –0.012 780.65
Sham acupressure vs standard care 2.10 0.018 117.98
Societal cost perspective
Acupressure vs standard care –358.74 0.005 –66,433.33 (acupressure dominates)
Acupressure vs sham acupressure –34.04 –0.012 2745.16
Sham acupressure vs standard care –324.70 0.018 –18,241.57 (sham acupressure 
dominates)
Bootstrapping
Acupressure vs standard care –40.64 0.005 –9025.53 (acupressure dominates)
Acupressure vs sham acupressure –90.26 –0.013 7163.27
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FIGURE 9 Cost-effectiveness plane for acupressure compared with standard care.
FIGURE 10 Cost-effectiveness plane for acupressure compared with sham acupressure.
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FIGURE 11 Cost-effectiveness acceptability curves for acupressure compared with standard care.
FIGURE 12 Cost-effectiveness acceptability curves for all three treatments.
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Net monetary benefit
Net monetary benefit was calculated for each patient and was found to be generally positive. NMB 
means (SD) were 5333 (1288), 5184 (1521) and 5489 (1261) for acupressure, standard care and sham 
acupressure respectively. Univariate ANOVA and linear regression models using age group, gender, 
emetogenic risk group, treatment allocation and baseline EQ-5D scores as covariates and independent 
variables were run to predict NMB.
Treatment allocation was not found to be a significant predictor of NMB. Only baseline EQ-5D score was 
found to be a significant contributor to the models. This is unsurprising as NMB is based partially on QALY 
values derived from the EQ-5D.
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Chapter 6 Qualitative data
Objectives
 z To outline patients’ experiences of using acupressure wristbands.
 z To outline the reasons why patients consent to take part in a clinical trial of acupressure wristbands.
 z To outline patients’ experiences of taking part in a randomised controlled trial of 
acupressure wristbands.
Findings
Sample
A total of 26 patients participated. Nine patients were recruited from Greater Manchester, nine from 
Merseyside and eight from Plymouth; in total, 10 patients had received true acupressure, nine had 
received sham acupressure and seven had not received any acupressure. The age range of the patients was 
35–79 years (mean 55 years) and seven were male and 19 were female. Nine of the sample were classified 
as receiving chemotherapy of high emetogenic potential, 12 as receiving chemotherapy of medium 
emetogenic potential and five as receiving chemotherapy of low emetogenic potential. How much nausea 
participants expected to experience during their chemotherapy treatment ranged from 0 to 10 (mean 5.8), 
with 0 being ‘not at all’ and 10 being ‘very frequently’; participants’ belief that the acupressure wristbands 
would help manage their sickness ranged from 2 to 10 (mean 6.9), with 0 being ‘not at all’ and 10 being 
‘will help me a lot’.
Themes
Deciding to participate
The majority of patients indicated that, after the initial approach by members of the research team, the 
decision to participate was immediate. In the time before consenting to take part (24+ hours), most did, 
however, discuss their intention to participate with significant others, typically partners and close family. 
Interestingly, patients attending one hospital appear to have been informed that if they participated 
in clinical trials it generated additional funds for the hospital, which appears to have influenced some 
patients to participate.
Well part of it he [consultant] did say that obviously it would be useful but also at the same time he 
did explain that obviously the more people that took part then you know it helped their side of things 
as well, like it got funded or something.
P318
I didn’t hesitate.
P382
Patients identified a range of factors influencing their decision to participate in the trial of acupressure 
wristbands. Undoubtedly the main motivational factor influencing patients was a desire to ‘give something 
back’. Almost all participants expressed an awareness of the fact that, without the willingness of 
patients to engage in research studies, it would be impossible for cancer care treatments and services to 
advance. In particular, it was the altruistic act of attempting to improve the care of future cancer patients 
that motivated patients to assist in evaluating whether or not acupressure wristbands are effective for 
chemotherapy-related nausea and vomiting.
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My reasons were as I’d had various treatments obviously associated with the diagnosis I’d had earlier 
that year it was partly that each time I had treatment I did reflect on people that had gone before me 
who from their experience and their participation in possible research that that perhaps made things 
easier for me in my experience. So it was a small way of trying to help for the future. That was kind of 
in my head, that I just wanted to try and be part of this and hopefully that would help people like me 
in the future.
P358
Well I thought if it helps somebody else in the future that is the only way they are going to find out 
the answers.
P411
Patients were aware that chemotherapy treatment is associated with a number of adverse side effects, 
including nausea and vomiting. A desire to limit their own experience of nausea and vomiting during their 
chemotherapy treatment was also a strong motivational factor for almost all patients. Of key importance 
was the fact that those patients participating in the trial may receive wristbands in addition to the 
antiemetic medication they would have received as part of their conventional care.
I just thought if I was to be going to be sick then it might be helpful.
P318
Because I could see all the list of things that you have . . . the after effects, you get tummy upsets and 
stuff like that. Then I thought, well, if that’s going to help me I don’t want to keep being sick, if it 
does help me I’ll have a go.
P351
A minority of patients indicated that the lack of any perceived risk of adverse effects from taking part in 
the trial was also a motivational factor when deciding to participate. Some of these patients elaborated, 
comparing participating in the trial of acupressure wristbands with participating in a pharmaceutical trial – 
specifically that the decision to participate would likely have been more considered if the trial had been for 
a new drug as opposed to a ‘natural’ remedy because of a perceived greater likelihood of adverse effects.
There would be no side effects, there would be nothing, there was, it was no detriment really . . . . I 
know you have got to help with these things, I think possibly yes [if pharmaceutical trial] I would have 
done but I would have had to know a lot more about it and a lot more in depth about it.
P280
Perceptions and experiences of complementary therapies
As part of the interview process participants were asked about their views and experiences of 
complementary and alternative medicine. Most patients had only limited personal experience of 
complementary and alternative medicine treatments before taking part in the trial; however, a number 
indicated that they had received additional complementary and alternative medicine treatments during 
their cancer treatment, such as reflexology, massage and reiki.
Some patients were aware of the current lack of an evidence base underpinning many complementary and 
alternative medicine treatments. Despite this patients frequently described themselves as ‘open-minded’ 
with regards to complementary and alternative medicine treatments and their effectiveness, often citing 
the successful treatment of family/friends or the long history of some of the treatments, with comments 
such as ‘it’s been around for years, so there must be something in it’ being common. Complementary 
and alternative medicine treatments were also perceived as being ‘natural’, ‘safe’ treatments associated 
with fewer side effects than conventional medicine. However, some patients, often those who had used 
complementary and alternative medicine treatments previously, held preconceived beliefs that many 
complementary and alternative medicine interventions were beneficial to patients whereas others held 
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an opinion that complementary and alternative medicine treatments were of little or no benefit to 
patients. For some, particularly those with a belief in the effectiveness and value of complementary and 
alternative medicine treatments, these preconceptions were identified as a further motivational factor 
when deciding to participate. Interestingly, some patients indicated that their involvement in the trial, or 
use of complementary and alternative medicine during chemotherapy, had altered their perception of 
complementary and alternative medicine; typically, their personal experiences of using complementary and 
alternative medicine made them more accepting of its potential value to patients.
I think a lot of people don’t realise that it’s beneficial and it helps. So yeah I think if more people 
realised and realised what help it does, you think oh complementary therapy it’s neither here nor 
there, but actually it does help you relax and you can forget about your troubles and what you’ve 
gone through and it’s just, it’s so relaxing and so nice. You just feel as though you could, you are just 
a million miles away.
P280
I can’t say whether it totally worked for me but for some people it must really assist them. Not it’s the 
way we have got to go, if it can save taking drugs, save ailments and acupuncture has been going on 
for quite a few years now [laughs] there must be something in it, for it to still keep going you know 
and so I have never experienced the needles or anything like that, but I understand and appreciate it 
must work because it is still going after what hundreds of years?
P334
Most patients saw the role of complementary and alternative medicine as being in combination with 
conventional medicine. Indeed, some patients indicated that they would be accepting of complementary 
and alternative medicine only if it was provided within the NHS, or if they were advised to use it by 
a treating conventional health-care practitioner. Irrespective of previously held views or experiences 
of complementary and alternative medicine interventions, participants were near unanimous in the 
importance they placed on research into complementary and alternative medicine, highlighting the 
importance of establishing whether or not treatments are effective for patients to use. There was also a 
view among some that there should be a greater integration of complementary and alternative medicine 
therapies and conventional therapies provided within the NHS but that this increasing integration should 
be underpinned by an emerging evidence base.
Yes I think any alternative therapy should be looked into, or to run not necessarily on its own but to 
run alongside you know, medicine.
P219
I think it’s very important [research into complementary and alternative medicine]. Yes. Because I see 
complementary medicine as being non-invasive, as being an aid to conventional medicines, or an 
add-on to conventional medicines. Yes.
P302
Experience of taking part in the trial
Only a couple of participants had any previous experience of taking part in research before agreeing to 
take part in the trial of acupressure wristbands. Interviewed patients typically indicated that they felt that 
they had a good understanding of the study before consenting to participate, with many recounting the 
written and verbal information they had received before consenting.
Yes I knew what it entailed and it was explained to me quite well.
P411
Part of this was being given information on the randomisation process to receive wristbands A, wristbands 
B or treatment as normal. Patients were typically pragmatic in their perception of the process, exemplified 
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by P280 who commented: ‘you are either going to be lucky if you get the wristbands and it might help, 
you are unlucky you don’t get anything and you just carry on as you would do if you wasn’t on the trial’.
However, despite this pragmatic approach, many allocated to treatment as normal still indicated that they 
felt ‘disappointment’ at not receiving wristbands.
Many participants expressed feeling daunted on initially receiving the paperwork for the trial. As one 
participant stated, ‘I thought oh crumbs [laughter]. I thought oh God every day.’ However, these feelings 
typically subsided once patients familiarised themselves with the forms and realised that forms were 
extensively duplicated. Participants generally felt that the included questionnaires were easy to follow, 
with comments such as ‘pretty straightforward’ being common. Although the questionnaires were easy 
to complete, a few patients felt that they were a little onerous, making comments such as ‘they were 
perhaps, perhaps a little bit too lengthy maybe’. Patients were asked to complete forms for the first 7 days 
following chemotherapy and on day 10. Some indicated that they failed to complete all of the paperwork 
on the designated days, in particular that lapses in memory, or poor health, led to forms sometimes being 
completed retrospectively. In some instances this could involve forms being completed up to 1 week after 
the date on which they were supposed to be completed. It was the difficulty of completing the paperwork 
when experiencing the adverse effects of chemotherapy that most patients felt resulted in some patients 
dropping out of the trial.
Some of the days when I was really, really poorly with the chemo I couldn’t even get out of bed to 
even fill it in I’ll be honest, but I knew each day how bad I was, how sick I was. So, you know, was 
able to fill it in accurately because I knew that at the beginning I was so poorly and so sick and by the 
end of it you are kind of coming round, so I knew from as soon as I come round and I was out of bed 
I filled it in.
P280
A number of patients felt that they had experienced positive outcomes as a result of taking part in the 
trial. Linked to patients’ motivations for taking part, most frequent was a sense of well-being as a result 
of feeling that they had completed an altruistic act and helped others. In addition, some patients felt that 
the process of completing the trial paperwork had been of benefit to them, specifically that it provided 
them with some control at a time when they felt a lack of control over their cancer experience or that they 
gained benefit from being able to reflect on how their symptoms had improved during previous cycles of 
chemotherapy. In contrast, some patients indicated that they had experienced some negative effects from 
completing the paperwork, chiefly that reading and rating their level of nausea and vomiting at a time 
when they were feeling nauseous had at times worsened their experience.
I think taking part in the trial is quite, it makes you feel better actually because it is a useful tool and 
it’s going to be of use for other people in the future . . . . Yes because it makes you feel better doesn’t 
it if you feel you are contributing something.
P250
I just completed the forms as requested and it was no hassle at all. And actually it helped because it 
was something positive to do, on certain days and ticking the boxes and all that sort of thing, I felt 
because I think part of having cancer is you lose control, and I am quite, the sort of person that likes 
to be in control and this is enabling me a little bit of control back, so that part I quite enjoyed actually.
P317
I know this sounds silly, funny almost, but some of the questions actually don’t help you when you’re 
not feeling well. You actually go oh, I feel sick reading out how many cups sort of, you know, sick.
P358
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Experience of using the wristbands
Those patients who were allocated to receive either true or sham wristbands during the trial were asked 
about their experiences of using them. Almost all patients interviewed appeared to have worn the 
wristbands as instructed, keeping them on for at least 7 days following chemotherapy and removing them 
only when washing or bathing. Indeed, some patients continued using the wristbands after the 7-day 
period, and many also continued using the wristbands after the four chemotherapy cycles included in 
the trial. Patients were asked to demonstrate how they wore the bands, with most of those interviewed 
apparently wearing the wristbands in the correct position. The exceptions were two patients allocated 
to receive sham wristbands, who were found to have worn them inappropriately. One patient wore the 
wristbands inside out (meaning that slight pressure would have been applied to the point) and the other 
patient indicated that he had manually applied pressure to acupoint P6.
Many of the patients interviewed indicated that they had experienced only mild nausea or vomiting during 
the trial. A number of patients were pragmatic about the extent to which the wristbands were responsible 
for this, highlighting the fact that there could be a number of other reasons, including their antiemetic 
medication, basic constitution or just luck. However, many patients, including some sham-treated 
patients, believed the wristbands to have had a positive impact on their nausea and vomiting. There was 
a perception and belief that the wristbands were, at least in part, responsible for the lack of nausea and 
vomiting they had experienced. In some cases this resulted from the patients’ experiences during the trial, 
such as noticing that nausea was greater when the wristbands were not worn. The wristbands were not 
seen as being any more or less effective at different times of the day or at different points in the patients’ 
chemotherapy treatment. There were also no additional benefits reported from wearing the wristbands 
beyond the alleviation of nausea and vomiting.
Until the trial is complete you can’t really say whether it helped you or not can you . . . . I wore them, 
yes I wore them each time I had treatment yes. And erm . . . yes I feel as though I benefited from them, 
and I think I possibly would have been more sick than what I was. I felt the bands did help in that 
respect. Yes.
P219
I must say I think, having learnt that I didn’t used to wear them for the first 2 weeks at first, but then I 
would be feeling a bit sick and I would think goodness me, why am I feeling so sick and then I would 
put them on and it would improve and one day I was feeling sick with them on, but they weren’t in 
the right place (laughs) I was looking at them and they weren’t in the right place, so there is a reason 
you know, this is why I have got such belief in them now.
P334
Patients reported that they had not experienced any restrictions from wearing the wristbands in terms of 
everyday activities, other than showering/bathing/washing dishes. As P297 commented, ‘I don’t have many 
household chores, but no not at all, not at all. I just, take them off when I have a bath or a shower, other 
than that no they are not intrusive at all‘. For most patients the wristbands were seen as comfortable to 
wear, although a few patients reported that they had experienced minor irritations, such as the wristbands 
feeling tight or painful, or the wrists becoming itchy. All reported adverse side effects were generally 
deemed minor and acceptable.
I find sometimes my, it gets, my skin gets quite red, and they rub and I am sure it’s because they are so 
badly made inside, I think that is the contributing factor.
P318
I did find the bobble that went into your arm painful a few times, and I sort of had to wriggle it 
around just sort of release the pressure on my arm just for a few minutes, rub my arm and then put it 
back in again.
P334
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A number of patients highlighted the fact that they had been questioned by others, both known to them 
and not, regarding their wearing of the trial wristbands. Many were unconcerned by the views of others. 
As P210 commented, ‘if they don’t like it, that’s their problem . . . didn’t influence me whatsoever’. 
However, a few patients highlighted that they had inhibitions about wearing them in the company of 
others or had received negative responses from others to their wearing of the wristbands. When asked 
about this, some compared the minor impact of wearing wristbands with such things as having to wear a 
headscarf or have surgical pointers on their body.
It’s a, it’s a silly point but they are there all the time, so you do sort of start pulling your sleeves down 
because you don’t want people to see them, you know it looks rather strange walking round with 
two wristbands on . . . Well everybody knew about them, because I, you know you chat to people 
and people ask you, and so, I would just tell people but if you went for a meal or if you were out 
somewhere socially where people didn’t know you, you would feel slightly embarrassed. These two 
bands, that look as though you should be in the gym.
P302
Irrespective of perceptions of effectiveness, almost all patients indicated that they would recommend the 
wristbands to other chemotherapy patients, or to patients experiencing nausea and vomiting from other 
causes. This related to the fact that, irrespective of whether or not the wristbands were of benefit for 
nausea and vomiting, they were not associated with any negative or adverse effects.
There isn’t a reason not to wear them. Personally yes. So, yes I would recommend them yes.
P194
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Chapter 7 Discussion
Key quantitative findings
Despite the higher proportion of patients showing no nausea in the acupressure group, the results 
of the trial show that there were no statistically significant differences between the three trial arms in 
relation to nausea experience. Patients in both wristbands arms had a higher OR for improving their 
nausea experience than those in the standard care arm, with the sham arm having a higher OR than the 
acupressure arm. There was a significant gender effect with women in both wristband groups showing 
significant improvements compared with men. Health-care utilisation was lower in the wristband arms 
than in the standard care only arm.
Other trials in the past have also shown no significant effects from the use of acupressure in relation to 
nausea and vomiting management during chemotherapy administration. A review by Lee and Frazier74 
examined the results of seven trials of acupressure, with four having positive results and three negative, 
highlighting that the overall effect of acupressure is strongly suggestive but not conclusive. No significant 
differences were reported in another trial of 160 women with regards to acute nausea and vomiting, 
although significant differences were reported with regards to delayed nausea and vomiting.75 In the 
largest trial of its kind (n = 739), Roscoe et al.24 showed that patients experienced less nausea in the first 
day of chemotherapy in the acupressure arms but there were no significant differences in relation to 
delayed symptoms. Also, the authors identified a strong gender effect, with men in an acustimulation 
arm improving but not women, which is in contrast to the results of the current trial. Roscoe et al.17 
also showed, in a small sample of 27 patients (25 women and two men), no statistically significant 
differences in average severity of nausea between acustimulation of the P6 point, sham acustimulation 
and standard care; however, the data showed a difference close to statistical significance in the severity 
of delayed nausea between active acustimulation and no acustimulation (p = 0.06). In addition, patients 
took fewer antinausea pills during the active acustimulation cycle of this experiment than during the no 
acustimulation phase (p < 0.05). Negative results have been shown in relation to acupressure and nausea/
vomiting symptoms in a large trial of 340 women during labour and delivery.76 In a trial of acupuncture 
compared with sham acupuncture during radiotherapy,77 the authors showed less nausea and vomiting in 
both the real and the sham acupuncture arms than in the standard care arm and justified this as due to 
non-specific effects of general care or high patient expectancy, which may partly explain our results too.
Key issues in most of the past studies showing positive results include the lack of standardised antiemetic 
use in the trial participants and inclusion of only or mostly female subjects. If our trial had included 
only the female subsample, the results would have also been positive. Also, it seems that the vast 
majority of positive studies in the literature include small sample sizes (< 100 participants), whereas the 
negative studies (or partly negative) have much larger sample sizes; this suggests that effects observed 
in methodologically weaker studies cannot always be sustained when larger and more robust trials are 
carried out. Furthermore, other studies in the past have shown that expectancy,24,78 age and anxiety28,29 
together with the antiemetic potential of the chemotherapy are important predictors of, and can affect, 
the outcome of acupressure, but in our trial, although unidimensionally these were also important, in a 
multivariate model only gender showed a significant effect.
Our findings suggest a placebo or non-specific effect of the intervention arms. Placebo effects are viewed 
as a form of interpersonal healing, distinct from spontaneous natural healing or technological healing 
that depends on physiologically active pharmacological products or procedures.79 Alkaissi et al.80 have 
suggested that acupressure does indeed have a placebo effect in relation to nausea after 24 hours, 
although correct stimulation of the P6 point is needed to observe decreased rescue antiemetic use and 
decreased vomiting. Research also suggests that there are different placebo responses, each of which may 
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be influenced by different psychological and neurobiological mechanisms depending on the context in 
which the placebo is given.81 The literature also shows that placebos have actual biological effects on the 
brain and body and are more than response biases. The review by Price et al.81 concludes that placebo 
effects reflect mind–brain–body relationships and as such we should not ‘resort to eliminative materialism 
or forms of dualism that completely divide the mind from the body’ (p. 586).
Trials of acupressure pose a specific problem with regards to the blinding and the choice of placebo, 
particularly when outcome measures are subjective. We have chosen to use the same wristbands in both 
the real and the sham groups so that they look identical, with the real acupressure group instructed to 
have the button pressing the P6 point and the sham group instructed to have the button pointing away 
from the P6 point on the other side of the arm. We observed during the interviews that some patients in 
the sham acupressure group (two out of nine) used the wristbands as in the acupressure group because 
they had looked on the internet or saw others wearing them properly. This may have contaminated our 
results. It was not possible to create a wristband that would look identical to the real one but which 
would not have a button or which would exert no pressure. These bands were elastic bands and, as 
reported by Sinha et al.76 (through observations from their colleagues in the Department of Industrial and 
Manufacturing Engineering, Penn State University, PA, USA), elastic bands result in some pressure. This 
suggests that the pressure of the band in the area proximal to the P6 point, irrespective of the presence of 
a button pressing the P6 point, may have produced some positive results.
Our sample had generally low levels of nausea and/or vomiting. This may be due to the fact that we 
have standardised antiemetic use in our study and an inclusion criterion was receiving antiemetics as per 
MASCC antiemetic guidelines. This low level of experienced symptoms may be a reason for not showing 
significant differences in the current trial, as we have shown in another observational study of nearly 1000 
patients that use of antiemetics during chemotherapy according to MASCC guidelines is associated with 
significantly improved nausea/vomiting symptoms.52
A limitation of the trial may be the missing data for the primary outcome. However, the proportion of 
cases missing the primary outcome (28%) is of a similar order to that anticipated at the design stage 
(33%). Originally 90% power had been planned for a standardised difference in means of around 0.48. 
For pragmatic reasons the study power was reduced to 80% so that it could complete in a reasonable 
time frame. The attained power that the final sample size with complete data for the primary outcome 
(n = 361) delivered was 80% for a standardised difference in means of 0.46. Also, another limitation that 
needs to be carefully considered in future trials is the choice of sham wristbands, which in our case may 
not have been the most optimal design.
Health-care utilisation data
Although there was no statistically significant effect of acupressure over sham acupressure and no 
acupressure, the health economics part of the trial was run concurrently with the effectiveness part of 
the trial. Through health economic analyses in negative trials it is possible that intervention benefits that 
are not apparent in traditional efficacy end points may register in QALYs, as this is a different composite 
outcome. Current thinking in respect of economic analyses in cases in which there is no clear differential 
effect/effectiveness of the intervention being assessed is that a full cost-effectiveness analysis is undertaken 
and uncertainty accounted for. Even given that the EQ-5D changes were below those levels that are 
minimally important and were not significant, and the QALY gains were minimal (for acupressure vs 
standard care), one cannot evaluate the cost-effectiveness without considering costs.82,83
Mean costs resulting from NHS resource use were consistently higher for the standard care only group 
than for the acupressure group; this finding was relatively robust to sensitivity analyses. However, because 
very little resource use was recorded in the study and the results may have been unduly influenced by 
outliers with high costs, this finding is relatively uncertain and must be treated with caution. The results 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Molassiotis et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17260 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 26
59
from the EQ-5D score analysis revealed no significant differences in utility changes over time between 
treatment arms and QALY gains throughout the study were negligible.
The acupressure bands group appears to have reduced health-care resource use while realising negligible 
improvements in quality of life compared with standard care alone. A rapid review of the literature 
found no studies including costs of chemotherapy-induced nausea and vomiting to the NHS, precluding 
comparison with previous research. Neither did the review yield any previous studies reporting EQ-5D 
scores for this patient group. In the present study the EQ-5D analysis showed no differences in utility 
between groups. There also appeared to be little overall impact of chemotherapy as no utility score 
changes between any cycle exceeded (or came close to exceeding) the minimal important difference 
identified for the measure. EQ-5D scores for older patients at the final chemotherapy cycle were similar to 
the population norm,84 but younger patients appeared to experience a greater utility decrement relative 
to norms. The mean utility for both the 25–50 and ≥ 50 age groups was 0.77 after cycle 4 compared with 
population norms of 0.90 for the 25–54 age group and 0.79 for the 55–74 age group. It is possible that 
the EQ-5D is not a sensitive enough measure to capture quality-of-life benefits that may be experienced as 
a result of reduced chemotherapy-induced nausea and vomiting, although a cancer-specific quality-of-life 
measure (FACT-G) also failed to detect any between-group differences. There is also a non-significant 
baseline difference in utility scores between groups, which may explain differential QALY gains over the 
trial period.
There were several limitations of this economic evaluation. We made assumptions regarding drug doses 
and antiemetics drug type because of missing data and also made assumptions regarding length of 
hospital stay. Assumptions were also necessary regarding the standard care of each of the patients, relying 
on expert opinion and assuming that care was the same across centres. It is possible that more expensive 
(branded) antiemetic treatments may have been used but not captured as not all prescribing information 
was available. Different sites may have different protocols relating to antiemetic prescription as a standard 
therapy. However, the ICERs and the resulting conclusions regarding the cost-effectiveness of acupressure 
were robust to sensitivity analyses and stochastic bootstrapping.
When calculating the EQ-5D missing data we employed the LOCF approach; this method assumes that 
the participant’s EQ-5D response would have been stable between each cycle, rather than declining or 
improving. It also assumes that missing values are ‘missing completely at random’ (i.e. that the probability 
of dropout is not related to variables such as disease severity, symptoms or drug side effects). As such, the 
LOCF method may lead to bias in the results. However, assumptions about both costs and utilities were 
tested in the sensitivity analyses. Finally, as stated above, it is possible that the EQ-5D is an inappropriate 
measure to capture health benefits incurred as a result of reduced nausea and that a cancer-specific 
measure may be more suitable.85 However, cost–utility analyses and the EQ-5D are compliant with the 
NICE reference case. Future research should consider cancer-specific utility measurement and comparisons 
with generic utility values. As the occurrence and impact of chemotherapy-induced nausea and vomiting 
varies over time in relation to chemotherapy receipt, quality-of-life impact depends on the time of measure 
completion during the cycle. Thus, research exploring patients’ health status on a daily basis throughout 
the course of a chemotherapy cycle may be warranted. Given the influence of high-cost outliers in the 
analyses, greater exploration of what is driving these costs and indeed whether or not they relate to 
chemotherapy-induced nausea and vomiting may be worthwhile; this may involve qualitative follow-up of 
high-resource-use individuals.
Qualitative data
The nested qualitative study aimed to explore patients’ reasons for taking part in a clinical trial of 
acupressure wristbands and their experiences of using acupressure wristbands and taking part in the trial 
of acupressure wristbands. The key findings from these data suggest that patients in the wristband arms 
perceived the bands to be effective and felt more in control of their nausea and vomiting experience.
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The motivations that patients identified for participating in the trial are congruent with the findings of 
previous research. Paterson et al.86 conducted a nested qualitative study exploring the experiences of 
patients with migraines receiving acupuncture within a randomised controlled trial. Similar to the present 
study, they found that patients felt that acupuncture was ‘worth a try’, with patients being eager for 
symptom relief and having a desire to help with research for altruistic motives, although the theme ‘giving 
something back’ appears to be much more prevalent within the present study. This may be a consequence 
of the greater morbidity associated with cancer, although further research would need to be conducted to 
confirm whether or not this is the case.
Patients were largely satisfied with the organisation and running of the trial. The process of recruitment 
was generally perceived as straightforward and to have been adequately described. Interestingly, the 
completion of trial paperwork was seen as being of benefit by some patients, a finding again consistent 
with previous research.86 Where the current study findings appear to differ from previous research is in 
the explicit feeling of ‘well-being’ that many patients experienced as a direct result of knowing that their 
participation in the trial might lead to the improvement of care for future cancer patients.
Previous qualitative research exploring the experiences of patients receiving treatment with acupuncture 
suggests that patients experience a range of benefits beyond the alleviation of their presenting condition, 
including improvements in overall well-being, sleep pattern and energy levels.54–56 A number of patients 
who received wristbands in the present study indicated that they had experienced only minor levels 
of nausea and vomiting during their chemotherapy. Some patients – those receiving both true and 
sham wristbands – attributed the wristbands as having had a positive impact on the level of nausea 
and vomiting experienced. However, none of the patients who participated in interviews associated the 
acupressure wristbands with eliciting benefits beyond the relief of chemotherapy-related nausea and 
vomiting. This may suggest that a greater stimulation of acupuncture points is required to elicit these 
effects or that the contextual factors within the acupuncture consultation, such as the interaction between 
the practitioner and the patient or consultation setting, may work in conjunction with the stimulation of 
acupuncture points to elicit these expanded effects of care.
The wristbands were not associated with any significant adverse effects and patients found them easy 
to wear and to be associated only with limited social inhibitions. Importantly, patients appear to have 
worn the wristbands in the correct location and for the period of time instructed. However, the data 
revealed that two of the nine sham acupressure group patients had worn their wristbands inappropriately 
(based on their trial arm allocation), either wearing them inside out or applying pressure manually to 
the acupoint. Also of importance is the apparent delay in some patients completing the trial paperwork, 
relying on memory to fill in the forms. Both of these may represent confounding variables, which if 
generalisable to other patients in the trial could have serious implications for the results of the trial.
Conclusions and research recommendations
Despite several acupressure antiemetic trials suggesting a beneficial effect, the trial heterogeneity and 
inconsistent findings prevented any definitive conclusions being drawn. Our study, using a strong 
methodological design and standardisation of antiemetics, showed no significant differences between 
acupressure and sham acupressure wristbands for the management of nausea and vomiting during 
chemotherapy. Nevertheless, the somewhat improved, albeit not statistically significant, levels of nausea 
in both wristband arms needs some attention, although, as minimally important differences in relation 
to chemotherapy-related nausea and vomiting are currently not established, some caution is necessary 
here. The use of wristbands led to lower health-care utilisation (although this did not reach statistical 
significance). Bands are well accepted and are low cost and safe additions to antiemetic drugs, but the 
ethical aspects of suggesting the use of potentially non-effective interventions that lead to lower health-
care costs and health-care utilisation need some careful consideration. There is a sufficiently encouraging 
signal and a suggestion of potential health resource-use benefits to justify exploration of acupressure 
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in further trials using both no intervention and sham acupressure controls. Questions that need to 
be answered in the future include whether or not other forms of acupressure such as regular finger 
acupressure or Korean hand acupressure could be more effective than wristband acupressure. A meta-
analysis of existing data on acupressure wristbands may be an appropriate way to provide a more concrete 
answer to the question of whether or not acupressure wristbands are effective in managing nausea and/or 
vomiting during chemotherapy.
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Appendix 1 Study scales: Rhodes Index of 
Nausea, Vomiting and Retching
Office use only
0 1 2 3 4 5 6 7 8 9
ANCHoR Trial
Date completed / /
d d m m y y y y
ANCHoR.Rhodes v1.0 19/02/2009
Rhodes Nausea & Vomiting Scale
Instructions:
Please mark the box for each question that most clearly corresponds to your experience. Please do not miss
out a question and place only one X in a box for each question. The ____ in statements represents
the selected phrase.
e.g.
7 or more
5-6
3-4
1-2
I did not throw up
throwing up, I have felt ____ distress:
severe
great
moderate
mild
no
to my stomach, I have felt ____ distress:
no
mild
moderate
great
severe
or sick to my stomach ____ times:
7 or more
5-6
3-4
1-2
no
5. In the last 12 hours, from nausea/sickness
dry heaves, I have felt ____ distress:
no
mild
moderate
great
severe
up I produced a ____ amount:
very large (3 cups or more)
large (2-3 cups)
moderate (1/2-2 cups)
small (up to 1/2 cup)
I did not throw up
or sick to my stomach:
not at all
1 hour or less
2-3 hours
4-6 hours
more than 6 hours
dry heaves without bringing anything up ____ times:
no
1-2
3-4
5-6
7 or more
2. In the last 12 hours, from retching and
cycle 1 2 3 4
Signed _______________________________
3. In the last 12 hours, from vomiting or 4. In the last 12 hours, I have felt nauseated
6. In the last 12 hours, each time I threw
7. In the last 12 hours, I have felt nauseated 8. In the last 12 hours, I have had periods of retching or
1. In the last 12 hours I threw up ____ times:
Copyright 1996. Curators of Missouri. Verna A. Rhodes, RN, EdS, FAAN
Day before chemotherapy
Day of chemotherapy
Day 1 after chemotherapy
Day 2 after chemotherapy
Day 3 after chemotherapy
Day 4 after chemotherapy
Day 5 after chemotherapy
Day 6 after chemotherapy
26237
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Appendix 2 Study scales: Multinational 
Association of Supportive Care in Cancer 
Antiemesis Tool
Office use only
0 1 2 3 4 5 6 7 8 9
ANCHoR Trial
ANCHoR.MAT.Acute v1.0 19/02/2009
Information and instructions:
Definitions:
Vomiting: The bringing up of stomach contents.
Nausea: The feeling that you might vomit.
Please place a firm cross in a single box per row. For question 2 and for the completion of dates
please use leading zeros if necessary e.g. 01/03/2008.
e.g.
How much nausea did you have in the last 24 hours?
0 1 2 3 4 5 6 7 8 9 10
None As much as possible
1) in the 24 hours since chemotherapy, did you have any vomiting? No Yes
MASCC Antiemesis Tool (MAT): Acute
Date completed / /
d d m m y y y y
Signed ______________________________________
3) in the 24 hours since chemotherapy, did you have any nausea? No Yes
4) If you had nausea, please enter the number that most closely resembles your experience.
2) If you vomited in the 24 hours since chemotherapy, how many times did it happen?
(Please use a leading zero if required e.g. 04)
Nausea and Vomiting during the first 24 hours after chemotherapy
(Please fill this section out the day after chemotherapy)
This section refers to the first 24 hours following chemotherapy:
cycle 1 2 3 4
28044
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Office use only
0 1 2 3 4 5 6 7 8 9
ANCHoR Trial
ANCHoR.MAT.Delayed v1.0 19/02/2009
Information and instructions:
Definitions:
Vomiting: The bringing up of stomach contents.
Nausea: The feeling that you might vomit.
Please place a firm cross in a single box per row. For the completion of dates please use leading
zeros if necessary e.g. 01/03/2008.
e.g.
MASCC Antiemesis Tool (MAT): Delayed
How much nausea did you have over this time period?
0 1 2 3 4 5 6 7 8 9 10
None As much as possible
5) Did you vomit 24 hours or more after chemotherapy? No Yes
Date completed / /
d d m m y y y y
Signed ______________________________________
7) Did you have any nausea 24 hours or more after chemotherapy? No Yes
8) If you had nausea, please enter the number that most closely resembles your experience.
Delayed Nausea and Vomiting
(Please fill this section out 4 days after chemotherapy)
6) If you vomited during this period, on how many days did it happen? 1 2 3 4
This section asks about the period from the day after to 4 days after chemotherapy.
So it asks about the time after the first 24 hours:
cycle 1 2 3 4
33150
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Appendix 3 Study scales: Functional Assessment 
of Cancer Treatment – General scale
Office use only
0 1 2 3 4 5 6 7 8 9
ANCHoR Trial
ANCHoR.FACTG v1.0 19/02/2009
FACT-G (Version 4)
Instructions:
Below is a list of statements that other people with your illness have said are important. By placing a firm
cross in one box per line, please indicate how true each statement has been for you during the past 7
days. e.g.
I have a lack of energy 0 1 2 3 4
I have nausea 0 1 2 3 4
Because of my physical condition, I have trouble meeting the needs of my family 0 1 2 3 4
I have pain 0 1 2 3 4
I am bothered by side effects of treatment 0 1 2 3 4
I feel ill 0 1 2 3 4
I am forced to spend time in bed 0 1 2 3 4
Not
at all
A little
bit
Some-
what
Quite
a bit
Very
much
PHYSICAL WELL-BEING
I feel close to my friends 0 1 2 3 4
I get emotional support from my family 0 1 2 3 4
I get support from my friends 0 1 2 3 4
My family has accepted my illness 0 1 2 3 4
I am satisfied with family communication about my illness 0 1 2 3 4
I am satisfied with my sex life 0 1 2 3 4
Not
at all
A little
bit
Some-
what
Quite
a bit
Very
much
SOCIAL/FAMILY WELL-BEING
I feel sad 0 1 2 3 4
I am satisfied with how I am coping with my illness 0 1 2 3 4
I am losing hope in the fight against my illness 0 1 2 3 4
I feel nervous 0 1 2 3 4
I worry about dying 0 1 2 3 4
I worry that my condition will get worse 0 1 2 3 4
Not
at all
A little
bit
Some-
what
Quite
a bit
Very
much
EMOTIONAL WELL-BEING
Regardless of your current level of sexual activity, please answer the following question.
If you prefer not to answer it, please check this box and go to the next section.
PLEASE TURN OVER
I feel close to my partner (or the person who is my main support) 0 1 2 3 4
cycle 0 1 2 3 4
31482
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ANCHoR Trial
Instructions:
By placing a firm cross in one box per line, please indicate how true each statement has been for you
during the past 7 days. e.g.
I am able to work (include work at home) 0 1 2 3 4
My work (include work at home) is fulfilling 0 1 2 3 4
I am able to enjoy life 0 1 2 3 4
I have accepted my illness 0 1 2 3 4
I am sleeping well 0 1 2 3 4
I am enjoying the things I usually do for fun 0 1 2 3 4
I am content with the quality of my life right now 0 1 2 3 4
Not
at all
A little
bit
Some-
what
Quite
a bit
Very
much
FUNCTIONAL WELL-BEING
ANCHoR.FACTG v1.0 19/02/2009
FACT-G (Version 4) - continued
PLEASE MAKE SURE YOU HAVE COMPLETED BOTH SIDES, THANK YOU
Date completed / /
d d m m y y y y
Signed _____________________________________
31482
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Molassiotis et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17260 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 26
79
Appendix 4 Study scales: Hospital Anxiety and 
Depression Scale
Office use only
0 1 2 3 4 5 6 7 8 9
ANCHoR Trial
Date completed / /
d d m m y y y y
ANCHoR.HADS v1.0 19/02/2009
Hospital Anxiety and Depression (HAD) Scale
Instructions:
This questionnaire is designed to help us know how you feel. Read each item and place a firm cross in the
box opposite the reply which comes closest to how you have been feeling in the past week.
Don't take too long over your replies; your immediate reaction will probably be more accurate than a long
thought out response. Please do not miss out a statement and place only one X in a box for each statement.
e.g.
I feel tense or 'wound up':
Most of the time
A lot of the time
From time to time, occassionally
Not at all
I still enjoy the things I used to enjoy:
Definitely as much
Not quite so much
Only a little
Hardly at all
something awful is about to happen:
Very definitely and quite badly
Yes, but not too badly
A little, but it doesn't worry me
Not at all
I can laugh and see the funny side of things:
As much as I always could
Not quite so much now
Definitely not so much now
Not at all
Worrying thoughts go through my mind:
A great deal of the time
A lot of the time
From time to time but not too often
Only occasionally
I feel cheerful:
Not at all
Not often
Sometimes
Most of the time
I can sit at ease and feel relaxed:
Definitely
Usually
Not often
Not at all
I get a sort of frightened feeling as if
I feel as if I am slowed down:
Nearly all the time
Very often
Sometimes
Not at all
I have lost interest in my appearance:
Definitely
I don't take so much care as I should
I may not take quite as much care
I take just as much care as ever
like 'butterflies' in the stomach:
Not at all
Occasionally
Quite often
Very often
I feel restless as if I have been on the move:
Very much indeed
Quite a lot
Not very much
Not at all
I look forward with enjoyment to things:
As much as I ever did
Rather less than I used to
Definitely less than I used to
Hardly at all
I get sudden feelings of panic:
Very often indeed
Quite often
Not very often
Not at all
I can enjoy a good book or radio or TV programme
Often
Sometimes
Not often
Very seldom
I get a sort of frightened feeling
cycle 0 1 2 3 4
Signed _______________________________
31777
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Appendix 5 Study scales: expectations and 
complementary therapy questionnaire
Office use only
0 1 2 3 4 5 6 7 8 9
ANCHoR Trial
ANCHoR.Expectations v1.0 20/02/2009
Instructions:
Please place a firm cross in a single box per row. A number of items are on a 0 to 10 scale with the
meaning of the extremes of the scale stated in words (please choose a value between 0 and 10 that best
represents your view).
e.g.
How much nausea (the feeling of being sick) do you think you will experience during your chemotherapy treatment?
0 1 2 3 4 5 6 7 8 9 10
Not at all Very frequently
How much do you believe that the acupressure method if allocated will help you manage your sickness better?
0 1 2 3 4 5 6 7 8 9 10
Not at all Will help me a lot
Have you used complementary therapies in the past? No Yes
Expectations and complementary therapy
Date completed / /
d d m m y y y y
Signed ______________________________________
How much vomiting (being sick) do you think you will experience during your chemotherapy treatment?
0 1 2 3 4 5 6 7 8 9 10
Not at all Very frequently
How much faith do you have in complementary therapies in general?
0 1 2 3 4 5 6 7 8 9 10
None at all Complete faith
45953
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Appendix 6 Study scales: sociodemographic 
characteristics questionnaire
Office use only
0 1 2 3 4 5 6 7 8 9
ANCHoR Trial
Date of birth / /
ANCHoR.Baseline v1.0 19/02/2009
Initials
Marital status
Single
Married
Divorced or separated
Widowed
Educational attainment
Primary school
Secondary school
College/Diploma
University/Degree
Postgraduate
Occupational group
Professional
Managerial & technical
Skilled non manual
Skilled manual
Unskilled
Not applicable
Occupational status
Employed full-time
Employed part-time
Retired
Unemployed
Casual worker
Not working due to ill health
Housewife
Other
Religious affiliation
Christian
Muslim
Hindu
None
Prefers not to say
Other
Ethnic origin
Caucasian
Black
Asian/Chinese
Mixed
Instructions: For choice fields please place a firm cross e.g. in a single box per item. For all numeric responses
(including dates) please complete all the boxes with leading zeros as required e.g. All dates are in
dd/mm/yyyy format.
0 5
d d m m y y y y
Gender
Male
Female
Smoking history
Never
Previously
Current
A little information about yourself
Date completed / /
d d m m y y y y
Signed _______________________________
38538
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Appendix 7 Study scales: acupressure wristband 
compliance questionnaire
Office use only
0 1 2 3 4 5 6 7 8 9
ANCHoR Trial
ANCHoR.Compliance v1.2 27/02/2009
Acupressure wristband compliance
Instructions:
Please mark the box for each listed day of this cycle of chemotherapy that most clearly corresponds to the
length of time that you have worn your wristbands. Please do not miss out a day and place only one X in a
box for each day e.g.
cycle 1 2 3 4
Signed _____________________________________________
Day of chemotherapy
Day 1 after chemotherapy
Day 2 after chemotherapy
Day 3 after chemotherapy
Day 4 after chemotherapy
Day 5 after chemotherapy
Day 6 after chemotherapy
None of
the time
A little of
the time
Most or all
of the time
4306
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Appendix 8 Wristband audit observation log
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Appendix 9 Health economics baseline 
questionnaire
ANCHoR Trial 
 
For office use only:   
 
Health Economics Baseline Questionnaire 
Use of health care services, medication and expenses incurred as a result 
of nausea or vomiting before chemotherapy 
 
Instructions: Over the next few weeks we will need to ask you some questions about the health 
care services you have used and anything you have had to buy because of any nausea or 
vomiting you may have experienced following chemotherapy. We are doing this to find out the 
costs of the different approaches to treatment.  This first questionnaire asks about any services 
used or anything you have had to buy because of any nausea or vomiting you have experienced 
in the last three weeks.  Some questions will seem more relevant to you than others, but please 
try to answer all the questions so that we can compare the costs of the treatments fairly.   
 
 
 
 
  
 
 
1. Please complete today’s date         
                                                                      DAY       MONTH       YEAR 
 
2. Please tick one box for the category that describes your present employment status. 
 
Employment Status Tick one category that best 
describes your employment 
now (please tick one box only) 
a. Employee, full time (more than 30 hours/week)  
b. Employee, part time (less than 30 hours/week)  
c. Self-employed  
d. Government-supported training  
e. Other training or education  
f. Employee on sick leave   
g. Not in paid employment due to retirement  
h. Not in paid employment for  other reasons  
 
Your date of birth:             
Hospital:   
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 9
92
If you are in paid work please tells us the number of days you have been away from 
work due to nausea or vomiting in the last three weeks.  
No of days         Not applicable  
 
Please estimate the earnings lost by to absence from work due to nausea or vomiting in 
the last three weeks? (bring home earnings).   
Earnings lost   £    Not applicable  
 
 
 
3. Have you used any health care services following nausea or because of vomiting in the last 
three weeks? 
 
Type of service 
Which services you 
have used in the 
last three weeks as a 
result of nausea or 
vomiting  
Total  number of 
face to face 
contacts  
Total number of 
contacts you had 
by telephone or    
e-mail  
GP surgery visit Yes     No    
GP home visit Yes     No    
District nurse,  Yes     No    
Contact with oncology 
hotline for advice 
Yes     No      
 
Contact with hospital 
oncology nurse clinician for 
advice 
Yes     No       
Contact with hospital 
oncology clinic for advice 
Yes     No       
Hospital inpatient stay Yes     No       
Hospital accident and 
emergency department 
Yes     No       
Hospital general outpatient 
clinic 
Yes     No      
 
Other services. Please specify 
in the boxes and for each 
service also provide number of 
contacts. 
   
 
1. 
2. 
 
3. 
 
1. 
2. 
 
3. 
 
1. 
2. 
 
3. 
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4. Were you prescribed any medication for nausea or vomiting following use of any of the above 
services?  
 
Type of service 
Medication 
prescribed for 
nausea or 
vomiting?  
Name of the 
medication 
No. of 
times dose 
to be taken 
per day 
Total No. 
of days 
medication 
prescribed 
Cost to 
you 
GP surgery visit Yes     No      
GP home visit Yes     No      
District nurse,  Yes     No      
Contact with 
oncology hotline 
for advice 
Yes     
No  
 
   
Contact with 
hospital oncology 
nurse clinician for 
advice 
Yes     No      
Contact with 
hospital oncology 
clinic for advice 
Yes     
No  
 
   
Hospital inpatient 
stay Yes     
No  
 
   
Hospital accident 
and emergency 
department 
Yes     
No  
 
   
Hospital general 
outpatient clinic 
Yes     
No  
 
   
Other services. 
Please specify in the 
boxes and for each 
service also provide 
number of contacts. 
Yes       No  
 
   
 
5. Did you incur any other expenses in the last three weeks due to nausea or vomiting? 
  
Yes 
 
No 
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6. If you have ticked ‘Yes’ to the previous question, please also describe the expenses that you 
have had to meet (for example, travel expenses, special diet or complementary therapy) in the 
table below. 
 
Brief description of item Cost to you (£'s )  
 £  
 £  
 £  
 £  
 
 
7. For each of the five sets of statements below, please tick the one box that best describes 
your own health state today. 
 
(i).  Mobility 
I have no problems in walking about….………………………..…………….  
I have some problems in walking about ……………………….……………. 
I am confined to bed ……………………………………………..……………. 
 
(ii).  Self-care 
I have no problems with self-care.…………………………….……………... 
I have some problems washing and dressing myself.………….………….. 
I am unable to wash or dress myself.…………………………….………….. 
 
(iii). Usual activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities.…………………... 
I have some problems with performing my usual activities.………............ 
I am unable to perform my usual activities.…………………………………. 
 
(iv).  Pain/discomfort 
I have no pain or discomfort.………………………………………………… 
I have moderate pain or discomfort.……………………………..…………. 
I have extreme pain or discomfort.………………………………………….. 
 
(v).  Anxiety/depression 
I am not anxious or depressed………………………………………………. 
I am moderately anxious or depressed.…………………………..………… 
I am extremely anxious or depressed.……………………………............... 
 
 
 
Thank you for completing this questionnaire. 
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Appendix 10 Health economics questionnaire
ANCHoR Trial 
 
For office use only:   
 
Health Economics Questionnaire 
Use of health care services, medication and expenses incurred as a result 
of nausea or vomiting following chemotherapy 
 
Instructions: We need to ask you some questions about the health care services you have used 
and anything you have had to buy because of any nausea or vomiting you may have experienced 
following your last cycle of chemotherapy. We are doing this to find out the costs of the different 
approaches to treatment.  Some questions will seem more relevant to you than others, but please 
try to answer all the questions so that we can compare the costs of the treatments fairly.   
 
 
 
 
  
 
 
1. Please complete today’s date         
                                                                      DAY       MONTH       YEAR 
 
2. Please tick one box for the category that describes your present employment status. 
 
Employment Status Tick one category that best 
describes your employment 
now (please tick one box only) 
a. Employee, full time (more than 30 hours/week)  
b. Employee, part time (less than 30 hours/week)  
c. Self-employed  
d. Government-supported training  
e. Other training or education  
f. Employee on sick leave   
g. Not in paid employment due to retirement  
h. Not in paid employment for  other reasons  
 
Your date of birth:             
Hospital:   
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If you are in paid work please tell us the number of days you have been away from work 
due to nausea or vomiting following your last cycle of chemotherapy?  
No of days        Not applicable  
 
Please estimate the earnings lost by to absence from work due to nausea or vomiting 
following your last cycle of chemotherapy? (bring home earnings).   
Earnings lost   £   Not applicable  
 
 
 
3. Have you used any health care services following your last cycle of chemotherapy as a result 
of feeling nauseous or because of vomiting (please only include services used after leaving the 
hospital following chemotherapy)? 
 
Type of service 
Which services you 
have used in the 
last three weeks as a 
result of nausea or 
vomiting  
Total  number of 
face to face 
contacts  
Total number of 
contacts you had 
by telephone or    
e-mail  
GP surgery visit Yes     No    
GP home visit Yes     No    
District nurse,  Yes     No    
Contact with oncology 
hotline for advice 
Yes     No      
 
Contact with hospital 
oncology nurse clinician for 
advice 
Yes     No       
Contact with hospital 
oncology clinic for advice 
Yes     No       
Hospital inpatient stay Yes     No       
Hospital accident and 
emergency department 
Yes     No       
Hospital general outpatient 
clinic 
Yes     No      
 
Other services. Please specify 
in the boxes and for each 
service also provide number of 
contacts. 
   
 
1. 
2. 
 
3. 
 
1. 
2. 
 
3. 
 
1. 
2. 
 
3. 
 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Molassiotis et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17260 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 26
97
4. Were you prescribed any medication for nausea or vomiting following use of any of the above 
services?  
 
Type of service 
Medication 
prescribed for 
nausea or 
vomiting?  
Name of the 
medication 
No. of 
times dose 
to be taken 
per day 
Total No. 
of days 
medication 
prescribed 
Cost to 
you 
GP surgery visit Yes     No      
GP home visit Yes     No      
District nurse,  Yes     No      
Contact with 
oncology hotline 
for advice 
Yes     
No  
 
   
Contact with 
hospital oncology 
nurse clinician for 
advice 
Yes     No      
Contact with 
hospital oncology 
clinic for advice 
Yes     
No  
 
   
Hospital inpatient 
stay Yes     
No  
 
   
Hospital accident 
and emergency 
department 
Yes     
No  
 
   
Hospital general 
outpatient clinic 
Yes     
No  
 
   
Other services. 
Please specify in the 
boxes and for each 
service also provide 
number of contacts. 
Yes       No  
 
   
 
5. Did you incur any other expenses due to nausea or vomiting following your last cycle of 
chemotherapy? 
  
Yes 
 
No 
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6. If you have ticked ‘Yes’ to the previous question, please also describe the expenses that you 
have had to meet (for example, travel expenses, special diet or complementary therapy) in the 
table below. 
 
Brief description of item Cost to you (£'s )  
 £  
 £  
 £  
 £  
 
 
7. For each of the five sets of statements below, please tick the one box that best describes 
your own health state today. 
 
(i).  Mobility 
I have no problems in walking about….………………………..…………….  
I have some problems in walking about ……………………….……………. 
I am confined to bed ……………………………………………..……………. 
 
(ii).  Self-care 
I have no problems with self-care.…………………………….……………... 
I have some problems washing and dressing myself.………….………….. 
I am unable to wash or dress myself.…………………………….………….. 
 
(iii). Usual activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities.…………………... 
I have some problems with performing my usual activities.………............ 
I am unable to perform my usual activities.…………………………………. 
 
(iv).  Pain/discomfort 
I have no pain or discomfort.………………………………………………… 
I have moderate pain or discomfort.……………………………..…………. 
I have extreme pain or discomfort.………………………………………….. 
 
(v).  Anxiety/depression 
I am not anxious or depressed………………………………………………. 
I am moderately anxious or depressed.…………………………..………… 
I am extremely anxious or depressed.……………………………............... 
 
 
 
Thank you for completing this questionnaire. 
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Appendix 11 Unit costs for the health economics 
analysis
Resource item
Face-to-face 
cost (£)
Telephone 
call cost (£) Source
GP surgery visit/contact 36 22 Curtis and Netten53 (p. 167) – with qualification, based on 
average visit time/telephone call
GP home visit 120 NA Curtis and Netten53 (p. 167) – with qualification, based on 
average time
District nurse 27 NA Curtis and Netten53 (p. 159) – per home visit including 
qualifications
Contact with oncology 
hotline for advice
N/A 8.50 Expert opinion
Contact with hospital 
oncology nurse clinician for 
advice
105 NA Department of Health87 – NHS trusts and PCTS combined – 
non-consultant led attendance non-admitted face to face
Contact with hospital 
oncology clinic for advice
129 NA Department of Health87 – NHS trusts and PCTS combined – 
consultant led attendance non-admitted face to face
Hospital inpatient stay 523 NA Curtis and Netten53 (p. 119) – non-elective (short)
Hospital accident and 
emergency department
37 (131a) NA Curtis and Netten53 (p. 119) – walk-in services leading to 
admitted (admitted/inpatient stay)
Hospital general outpatient 
clinic
136 NA Curtis and Netten53 (p. 119) – outpatient procedures, 
weighted average of all adult outpatient attendances
NA, not applicable.
a The cost of admission.
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Appendix 12 Drug costs used for the health 
economic analysis
Antiemetic/drug Dose Cost Source
Cyclizine (Valoid, 
Amdipharm)
Orally – 50 mg three 
times a day for 7 days
50 mg, net price 100-tablet pack = £7.41 BNF64
Domperidone Orally – 20 mg four times 
a day for 7 days
10-mg tablets/pack size 30 = £0.28; two 
packs = £0.56
eMIT63
Ondansetron Intravenously – 8 mg on 
day of chemotherapy
8 mg/4 ml solution for injection ampoules/pack 
size 5 = £1.94 = £0.39 per injection
eMIT63
Orally – 8 mg twice a day 
for 3 days
8-mg tablets/pack size 10 = £0.99
Dexamethasone Intravenously – 8 mg on 
day of chemotherapy
8 mg/2 ml solution for injection vials/pack size 
5 = £8.37 = £1.67 per injection
eMIT63
Orally – 8 mg 1 day, 4 mg 
1 day, 2 mg 1 day
2-mg tablets/pack size 50 = £2.08
Palonosetron (Aloxi, IS 
Pharmaceuticals)
Intravenously – 250 µg on 
day of treatment
50 µg/ml, net price 5-ml ampoule = £55.89; five 
ampoules = £279.45
BNF64
Metoclopramide Orally – 10 mg four times 
a day for 7 days
10 mg, net price 28-tablet pack = £0.17 eMIT63
Ondansetron (Zofran) Orally – 8 mg 1–2 hours 
before treatment
4 mg, net price 30-tablet pack = £107.91 BNF64
Levomepromazine 
(Nozinan, Sanofi-
Aventis)
Orally – 12.5 mg daily for 
7 days
25 mg, net price 84-tablet pack = £20.26 BNF64
Granisetron Intravenously – 3 mg on 
day of chemotherapy
3 mg/3 ml solution for injection ampoules/pack 
size 5 = £7.95 = £1.59 per injection
eMIT63
Orally – 2 mg daily for 
3 days
2-mg tablets/pack size 5 = £5.88
Aprepitant (Emend, 
Merck, Sharp & Dohme)
Orally – 3-day pack, one 
pack per cycle
Day pack of one 125-mg capsule and two 80-mg 
capsules = £47.42 
BNF64
Prochlorperazine 
(Buccastem, Alliance/
Stemetil, Sanofi-Aventis)
Orally – 2.5 mg daily for 
7 days
3 mg, net price 5 × 10-tablet pack = £5.89 BNF64
Haloperidol Orally – 1.5-mg tablets, 
one a day for 7 days
1.5-mg tablets/pack size 28 = £1.66 eMIT63
Lansoprazole 30 mg daily for 21 days 30-mg gastroresistant capsules/pack size 
28 = £1.14
eMIT63
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Appendix 13 Protocol
Project Title
The effectiveness and cost effectiveness of acupressure for the control and management of chemotherapy-
related acute and delayed nausea.
Research objectives
Primary objective:
1. To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care 
in the management of chemotherapy-induced (acute and delayed) nausea compared to patients 
receiving standard care with sham acupressure wristbands and standard care alone.
Secondary objectives:
2. To assess the cost effectiveness and extent of use of usual care in patients using acupressure 
wristbands in addition to standard care for the management of chemotherapy-induced nausea 
compared to patients receiving standard care with sham acupressure wristbands and standard 
care alone.
3. To assess the level of quality of life in patients using acupressure wristbands in addition to standard 
care in the management of chemotherapy-induced nausea and vomiting compared to patients 
receiving standard care with sham acupressure wristbands and standard care alone.
4. To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care 
in the management of chemotherapy-induced (acute and delayed) vomiting compared to patients 
receiving standard care with sham acupressure wristbands and standard care alone.
5. To ascertain for which emetogenic level of chemotherapy regimens (ie. high, moderate or low 
emetogenic chemotherapy) self-acupressure using wristbands in addition to standard care is more or 
less effective in terms of nausea compared to patients receiving standard care with sham acupressure 
wristbands and standard care alone.
6. To ascertain whether any improvement in chemotherapy-induced nausea and vomiting from using 
acupressure wristbands is different in males and females.
7. To ascertain whether there is an age effect from the use of acupressure wristbands in relation to 
chemotherapy-induced nausea and vomiting.
Existing research
Significant developments in antiemetic therapy over the past two decades have improved the control of 
chemotherapy-related vomiting. By contrast, chemotherapy-related nausea, both acute and delayed, is still 
a significant problem in clinical practice, with 42–52% of patients experiencing nausea on any one day in 
routine practice (Glaus et al, 2004). Surprisingly, despite improvements in the management of vomiting, 
post-chemotherapy nausea seems to have increased (Roscoe et al, 2000). Furthermore, clinicians often 
underestimate the experience of nausea, especially with regards to delayed nausea (Grunberg et al, 2004; 
Liau et al, 2005).
Chemotherapy-induced nausea and vomiting (CINV) can have a profound effect on the cancer treatment 
experience (Bergkvist & Wengstrom, 2006) and is associated with negative effects on daily life and overall 
quality of life, including effects on food intake, weight loss, effects on social interactions, dehydration, 
difficulty with sleeping and anxiety (Bergkvist & Wengstrom, 2006; Foubert & Vaessen 2005). In a 
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qualitative study of patients’ experiences, unmanaged nausea was constant in some patients and made 
them exhausted for long periods after chemotherapy, making recovery between cycles longer (Bergkvist 
& Wengstrom, 2006). The impact of nausea is greater than that of vomiting (Griffin et al, 1996) and 
nausea has proven to be more difficult to control. The direct and indirect costs of the experience of nausea 
and vomiting, especially of delayed symptoms, are considerable (Ihbe-Heffinger et al, 2004). Antiemetic 
trials have traditionally focused primarily on vomiting and emetic episodes, upon which the effectiveness 
of many antiemetic drugs is judged. Little attention has been directed to the concept of chemotherapy-
induced nausea despite the fact that it is increasingly recognised that nausea and vomiting are related but 
separate entities (ASHP 1999; Miller & Kearney 2004). The need for these two symptoms to be treated as 
two separate entities is strongly advocated (Miller & Kearney 2004).
The reasons behind this incomplete management of CINV are multifaceted. They include health 
professionals’ limited understanding of the complex concept of CINV and its different phases; limited 
assessment in clinical practice of CINV and its risk factors; using more emetogenic chemotherapy protocols 
than in the past; not understanding clearly all the pathways involved in the development of CINV; and 
more focus given to the vomiting experience than nausea in clinical trials (Molassiotis, 2005).
As antiemetic medications do not fully control nausea during chemotherapy, non-pharmacological 
interventions in addition to antiemetics have been tested over the years, especially in the 1980s, including 
relaxation techniques, coping preparation, imagery, and distraction techniques, with positive results in 
most studies (for a review see Burish & Tope, 1992). Acupuncture and its non-invasive form of acupressure 
have been tested several times after the classic early work of Dundee (1987; 1989). In a literature 
search using the key words ‘acupressure’, ‘nausea’, ‘vomiting’, ‘emesis’, ‘chemotherapy’, ‘cancer’ and 
combinations, we have identified 10 studies specific to oncology, reviewed elsewhere (Molassiotis et al, 
2007a), with 7/10 studies showing positive results and a further two approaching statistical significance. 
These studies have used a variety of acupressure methods, such as the ‘ReliefBand’ (a small battery-
operated TENS device designed to stimulate the P6 acu-point) (Pearl et al, 1999; Roscoe et al, 2002; Treish 
et al, 2003); a SeaBand (a small elastic band with a round plastic button applying constant mild pressure 
on the P6 acu-point) (Dundee & Yang, 1990; Dundee et al, 1991; Wright 2005); direct pressure on the 
acu-point P6 (Shin et al, 2004) or P6 and ST36 points together (Dibble et al, 2000). Most studies had small 
sample sizes of 18–50 patients. The largest study to date (n = 739) testing acupressure and acustimulation 
showed improvements in nausea and vomiting in men while there was a similar trend in women to reduce 
acute symptoms only, although the latter did not reach statistical significance (Roscoe et al, 2003). No 
improvement in nausea/vomiting was shown in a small study by Roscoe et al (2005) in women with breast 
cancer using acustimulation (ReliefBand) wristbands. The latter two studies are suggestive of a possible 
gender effect. However, most past studies are hampered by small sample sizes, the wide variety of (non-
standardised) antiemetics used, differences in the risk factors for nausea and vomiting in these samples, 
the range of emetogenicity of chemotherapy regimens used and sampling issues. A recent Cochrane 
systematic review of the literature highlights that acupressure reduces acute nausea but not delayed 
nausea, and has no benefit for vomiting (Ezzo et al, 2006). However, the review was primarily focused on 
acupuncture rather than acupressure, all different methods of acupressure were examined together and 
the results regarding specifically vomiting are questionable (as many of the studies included in the review 
had samples with little, if any, vomiting across experimental and control groups).
Our own work
Over the past 8 years the lead applicant has developed a programme of research in the management of 
chemotherapy-induced nausea and vomiting that feeds into the current application. This has involved 
the assessment of the effectiveness of non-pharmacological interventions for the management of CINV 
including progressive muscle relaxation training and imagery techniques (Molassiotis et al, 2002a); pilot 
testing of acupressure (Molassiotis et al, 2007a); identification of risk factors for CINV development 
such as age, gender and anxiety (Molassiotis et al, 2002b); the management of anticipatory nausea and 
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vomiting (Aapro et al, 2005), the development of international clinical guidelines for managing CINV 
(Roila et al, 2006) and radiation-induced nausea and vomiting (Maranzano et al, 2006); exploration and 
further clarification of the concept of chemotherapy-induced nausea as a separate entity from vomiting 
(Molassiotis et al, 2008a), the assessment of CINV levels in current clinical practice in the UK (Molassiotis 
et al, 2008b) and the development of a CINV relevant clinical scale for the assessment of acute and 
delayed symptoms (Molassiotis et at, 2007b). The latter is the only chemotherapy-specific scale available 
to date. In our qualitative study of the experience of chemotherapy-related nausea in seventeen patients 
with cancer in the UK and USA, nausea was described as distressing and complex symptom (Molassiotis 
et al, in press-a). Preliminary evidence indicates that nausea is part of a cluster of symptoms. Self-
management techniques, such as dietary strategies and distraction techniques, were rooted in participants’ 
understanding of nausea and their beliefs about what caused nausea. While self-management was 
common in almost all patients, acupressure was not one of the approaches used. In our latest study, 
an observational prospective evaluation using patient self-reports, 102 patients with cancer receiving 
their first chemotherapy treatment participated. They were followed up for 4 cycles of chemotherapy, 
providing a total of 272 assessments of nausea and vomiting. The results indicated that acute vomiting 
was experienced by 15.7% of the patients in cycle 1 and delayed vomiting by 14.7%, while acute nausea 
was present in 37.3% of the patients and delayed nausea in 47.1%, which increased over the four cycles. 
Moderately emetogenic chemotherapy had the highest incidence of CINV and acute symptoms were more 
controlled than delayed symptoms. The data suggested that, while vomiting is relatively well controlled, 
nausea is a significant problem in practice; it also highlighted the high cost of inappropriate use of 
antiemetics, which was £17,524 for every 100 patients treated over 4 cycles (Molassiotis et al, 2008b).
Research methods
The design of the study will be a randomised controlled trial with 3 arms. Each arm will consist of usual 
care plus one of (1) self administered acupressure wristbands, (2) sham acupressure wristbands, and (3) 
no additional treatment. The duration of the patients’ involvement will be for four cycles of chemotherapy, 
as after 4 cycles patients not responding to the given chemotherapy may discontinue it, may be offered a 
different chemotherapy regimen, a different treatment plan or may be offered supportive care only.
Subjects will be allocated to the trial groups through computer-generated randomisation to be carried out 
remotely by the trials unit of the Christie Hospital NHS Foundation Trust. The randomisation method to be 
used will consist of minimisation with a random element (stochastic minimisation), balancing for gender 
(males/female; Molassiotis et al, 2002b; du Bois et al, 1991), age (16–24; > 24–50; > 50; Molassiotis et 
al, 2002b; Morrow et al, 1991) and three levels of emetogenic chemotherapy (low, moderate and high 
according to international ASCO and MASCC classifications; Kris et al, 2006; Roila et al, 2006).
Biases will be minimised through: a) carefully developed inclusion and exclusion criteria that take into 
consideration the range of factors and sources of nausea and vomiting in cancer patients other than 
chemotherapy (ie. intestinal obstruction); b) the use of covariates for variables that are closely linked 
with nausea and cannot be excluded as they are present in a large proportion of the population (ie. 
anxiety) (Molassiotis et al, 2002b; Andrykowski et al, 1992), to be incorporated during the data analysis 
as a covariate in ANCOVA models; and c) the use of stratification for other key risk factors for nausea 
development during chemotherapy (ie. age, gender) at the randomisation stage. Stratification, prior 
to randomisation, is important to ensure that known prognostic factors are equally distributed before 
measuring the treatment-related variables.
Pilot study using this design
We have carried out a two-arm pilot study of 36 breast cancer patients using acupressure wristbands 
(Sea Band) (Molassiotis et al, 2007a). The current application is based on methods tested in this pilot 
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study. While it is acknowledged that this study was limited, key findings suggested that acupressure 
improved the nausea experience as well as nausea and vomiting occurrence and distress across the first 
five days of chemotherapy. Nevertheless, improvements were higher in relation to nausea than vomiting. 
Mean percentage of improvement was 44.5% in the experimental subjects over the control subjects. The 
study showed that an acupressure trial is feasible, with high levels of compliance (only 1 patient stopped 
using wristbands due to arm swelling), although one-third of the patients did not return completed 
assessments. The lack of follow up techniques (ie. reminder letters), which was due to time constraints, is 
partly responsible for this figure, and it is acknowledged as a limitation of the pilot study. However, missing 
data in the returned assessments was almost non-existent, and patient logs for acupressure usage were 
fully completed.
The use of sham acupressure and acupressure have also been used in another pilot trial we have carried 
out recently for the management of cancer-related fatigue (Molassiotis et al, in press-b), and it was shown 
that patients in the sham group who were informed they were receiving one of two combinations of 
(acu)-points were blinded until the end of the trial and that this group had little improvement compared 
to the real acupressure group, suggesting that this technique was a credible placebo and thus capable of 
minimising the likely effect of placebo on the study’s findings.
Planned interventions, both experimental and control
The design of the study involves a phase III pragmatic randomised trial.
Sample: The target population will be a heterogeneous group of cancer patients meeting inclusion criteria 
and about to receive chemotherapy of high, moderate and low emetogenic potential. Heterogeneity is 
important in order to address issues of response to different types of emetogenic chemotherapy, and 
by gender and age, as past literature highlights these are important in assessing the effectiveness of 
treatments for chemotherapy-related nausea and vomiting. Minimally emetogenic chemotherapy will not 
be included, as clinical guidelines recommend no antiemetic treatment and the nausea/vomiting level is 
< 10%.
In the acupressure group, in addition to standard antiemetics, patients will be provided with a pair of 
SeaBand wristbands (Sea-Band Ltd, Leicestershire, UK). These bands are elastic wristbands with a 1 cm 
protruding round plastic button (stud). These are available in two sizes, a standard one and a larger one. 
Patients wear the wristband with the stud pressing the P6 acu-point, which is located on the anterior 
surface of the forearm, approximately three-finger width up from the crease of the wrist between 
the tendons of the Palmaris longus and flexor carpi radialis. Patients will be provided with a pair of 
acupressure wristbands and they will be instructed to wear them on both arms and take them off only 
when showering/bathing. An instruction sheet with a picture of point P6 and how to locate the point will 
also be provided to patients. Patients will be instructed to wear the wristbands from the morning before 
chemotherapy administration and for the subsequent 6 days (total = 7 days). No other complementary 
therapies use will be recommended during the course of acupressure (although any such use will 
be documented).
In the sham acupressure group, in addition to standard antiemetics, patients will be provided with a 
pair of the identical appearing wristbands, with the only difference being that the sham wristband will 
have a flat button (made from felt) in place of the protruding stud, thus exerting no pressure on the P6 
point. There is an ongoing scientific debate on what constitutes an appropriate sham treatment, and it is 
acknowledged that there is no sham method in acupuncture and acupressure studies that can be widely 
accepted as the optimal method. It is now increasingly believed that sham acupuncture/acupressure 
designs cannot detect the whole placebo effect and may generate false negative results (Paterson & 
Dieppe, 2005; Kaptchuk et al, 1996; Mason et al, 2002; White et al, 2001), depending on the method 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Molassiotis et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17260 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 26
107
used. We have debated the appropriateness of other sham methods, but either they were not blinded 
enough for the purposes of the trial (ie. had to be slightly dissimilar to real acupressure wristbands) or 
could be perceived as treatments themselves (ie. acupressure at other points in the forearm or elsewhere 
where we have no information as to an effect on the experience of nausea). Patients in the clinics could 
also talk to each other and realize they have different interventions or check the P6 point on the internet. 
Hence, we resolve to use an acupressure technique which appears to be exactly the same as the active 
treatment with the only exception being the type of stud used. This was also agreed by practitioners too, 
who have been consulted about their views on the most appropriate sham method. Furthermore, while it 
is acknowledged that many patients may have heard of the use of such wristbands, the results of our pilot 
study suggest that their understanding of how acupressure works is limited (Molassiotis et al, 2007a). In 
addition, the results of our qualitative study on self-management of CINV suggest that acupressure is not 
commonly used by patients (Molassiotis et al, 2008a). An assessment of patient blinding at the end of the 
trial will also be incorporated in this trial.
The control group will receive standard antiemetics alone. Standard antiemetics for all three groups will 
be based on ASCO and MASCC international antiemetic guidelines with the exception of NK1 receptor 
antagonists (ie. aprepitant) recommended in highly emetic chemotherapy, which is not available currently 
in the NHS. Hence, for highly emetic chemotherapy, patients should receive a 5-HT3 receptor antagonist 
(ie. Zofran 8 mg) and dexamethasone 8 mg intravenously before chemotherapy and the same orally for 
3 days post chemotherapy; for moderately emetogenic chemotherapy a 5-HT3 receptor antagonist (Zofran 
8 mg) and dexamethasone 8 mg intravenously before chemotherapy and a 5-HT3 receptor antagonist 
or dexamethasone (preferred) for 2 days post-chemotherapy; and for low emetogenic chemotherapy 
dexamethasone 8 mg before chemotherapy and no other treatment post chemotherapy (Kris et al, 2006; 
Roila et al, 2006). All patients will receive rescue antiemetics if nausea and/or vomiting is persistent and 
fail to respond to the antiemetic treatment (ie. severe nausea or > 5 vomiting episodes), based on the 
experience of each clinician (as agreed guidelines for rescue antiemetics have not been developed to date).
During the course of the trial, three focus group interviews will be organised with 6–8 patients in each 
of these groups who have received active acupressure. An attempt will be made to also include patients 
who have dropped out from the trial. This will be an exploratory nested qualitative study within the trial 
to explore the patients’ experience of receiving acupressure, how they found the use of acupressure, 
whether the wristbands impacted/restricted the patients daily living, if they would recommend the use of 
wristbands to others, and whether there were any perceived effects or benefits beyond the CINV. It will 
also attempt to tease out from subjects reasons for non-compliance (if any) and difficulties the patients 
experienced wearing these bands. Data will be recorded and transcribed verbatim, at which point it will be 
analysed using standard content analysis methods.
Planned inclusion/exclusion criteria
Inclusion criteria:
 z Patients scheduled to receive their first chemotherapy cycle.
 z Patients scheduled to receive highly, moderately and low emetogenic chemotherapy (as per ASCO and 
MASCC classifications).
 z Patients scheduled to receive a chemotherapy regime as a single or multiple administration repeated 
every 2-week, 3-week or 4-week cycles.
 z Patients who are acupressure wristband-naïve (in terms of never having tried for themselves such a 
wristband, although they may have seen or heard about such wristbands).
 z Patients of either gender and older than 16 years old.
 z Patients with any cancer diagnosis receiving chemotherapy without concurrent use of radiotherapy.
 z Patients receiving chemotherapy as outpatients or inpatients.
 z Patients willing to participate in the study and be randomised into one of the three study groups.
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Exclusion criteria:
 z Patients scheduled to receive radiotherapy concurrently with chemotherapy and during the assessment 
period of four cycles for each patient.
 z Patients unable to self care (ie. unable to use wristbands appropriately; mental incapacity preventing 
continuous and optimal use of wristbands) as judged by the investigators.
 z Patients with liver disease (as nausea is common presenting symptom).
 z Patients with metabolic risk factors for nausea (ie. electrolyte imbalances causing nausea/vomiting).
 z Patients with mechanical risk factors for nausea (ie. intestinal obstruction).
 z Patients experiencing nausea and/or vomiting due to use of opioids.
 z Patients with lymphoedematous arms.
 z Patients with chronic alcohol use (as it is associated with minimal levels of nausea and/or vomiting).
Proposed sample size
In our pilot study (Molassiotis et al, 2007a), the mean score for nausea experience averaged over 5 days 
was 2.79 (weighted average SD 3.15) in the control group and 1.45 (weighted average SD 2.76) in the 
intervention group. At least 135 participants per arm would be required to detect this pair wise difference 
between arms using a t-test with a conservative Bonferroni-adjusted significance level of 0.05/3 = 0.017 
at a power of 90%. The pilot study suggested an attrition rate of 33%, so initially, at least 202 participants 
would be required per arm. As the standard deviations (SDs) are much larger than the means in the pilot 
data, they are suggestive of highly skewed distributions; hence the equivalent nonparametric test (the 
Mann–Whitney test) will be used. As the asymptotic relative efficiency of the Mann–Whitney test is at 
worst 0.864, the sample size for a Mann–Whitney test is, in the worst case, equal to the sample size for 
the t-test divided by 0.864. This would increase the required sample size to 156 per arm before attrition, 
233 after attrition, totaling 699 across the three arms.
Recruitment will take place in the largest single-site cancer centre in the UK, and cancer units or centres 
of district general hospitals and university hospitals, including the Christie Hospital NHS Trust and its 
peripheral clinics where chemotherapy is administered (Oldham Hospital & Tameside Hospital), Hope 
Hospital in Salford and Trafford General Hospital, the Liverpool Royal Infirmary and three cancer units 
associated with the University of Plymouth (South Devon Healthcare NHS Foundation Trust, Plymouth 
Hospitals NHS Trust, Royal Cornwall Hospitals NHS Trust). Available statistics from the Christie Hospital 
NHS Trust alone show that around 9,000 patients receive chemotherapy every year, with approximately 
two-thirds of these patients receiving chemotherapy in 3-weeks cycles. Recruitment rates are based on 
a similar antiemetic study we have conducted over four cycles of chemotherapy (Molassiotis et al, under 
review), where it has taken us 6 months to recruit 102 patients and retain 65% over the four cycles of 
chemotherapy. Based on similar recruitment levels at each of the 9 sites listed above, we estimate that 
recruitment will be completed in 16 months, with a further 3 months required to complete the follow up 
of the final patients.
Statistical analysis
Appropriate descriptive statistics will be estimated for all baseline socio-demographic and clinical variables 
by arm, and for outcome variables (scores on nausea and vomiting subscales) by arm. The association 
between baseline socio-demographic or clinical variables and outcome variables will be assessed using 
appropriate between-group tests or correlations depending on skewness. Primary outcome variables will 
be compared between the arms using t-tests, one-way analysis of variance, Mann–Whitney tests and 
Kruskal–Wallis tests, bearing in mind any skewness in the data. Mixed models (repeated measures analysis 
of variance with between-group factors and anxiety as covariate) will be used to compare outcome 
variables measured at repeated time points between the arms. An intention-to-treat analysis model will 
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be followed. As the primary outcome variable will be assessed over several days repeatedly, an aggregate 
score of all assessments in each cycle will be calculated before any modeling analysis.
The effect of missing values will be assessed by comparing the numbers and percentages of participants 
with missing values in the three arms of the study; differences in baseline variables between participants 
with observed and missing outcomes in each arm; and for participants with observed outcomes, 
differences in baseline variables between the three arms. Logistic regression models will be used to assess 
potential factors affecting drop-out.
For the interview part of the trial, data will be tape-recorded and transcribed verbatim, at which point it 
will be analysed using content analysis methods. This will include identifying key themes and developing 
categories using the interview questions as the framework of analysis.
Proposed outcome measures
Primary outcome:
#Rhodes Index of Nausea & Vomiting (Rhodes & McDaniel, 1999). This is a 12-item validated scale 
measuring nausea and vomiting experience, incidence and severity. This 12-item scale, taking 2–3 min to 
complete, will be done daily from the day before chemotherapy (to capture any anticipatory nausea) up to 
seven days post chemotherapy (= 8 assessments/cycle).
Secondary outcomes:
#MASCC Antiemesis Tool (MAT) designed by the Multinational Association of Supportive Care in Cancer 
(MASCC) (Molassiotis et al, 2007b). This 8-item scale assesses in a simple way both acute and delayed 
nausea and vomiting incidence and extent and was designed specifically for chemotherapy-related nausea 
and vomiting. This short clinical scale has shown satisfactory internal reliability (α = 0.77), contrasted-
groups and concurrent validity, and high recall of events up to 3 weeks post chemotherapy. The MAT 
is designed to be used once-per-cycle with retrospective patient recall of events, minimising the patient 
burden. Factor analysis has clearly identified three factors, namely vomiting, acute nausea and delayed 
nausea (Molassiotis et al, 2007b). The scale will be completed at day 10 of each cycle (= 4 assessments).
#FACT-G. This is a well-validated quality-of-life scale focusing on functional assessment (Fairclough & 
Cella, 1996). This functional scale will not only provide quality-of life-indications, but also changes in other 
symptoms/side effects that may have resulted from any improved management of nausea (ie. appetite). 
High internal consistency and construct validity have been reported in past studies using the FACT scales in 
various cancer populations. Completion time is about 5 min. This scale will be completed at baseline and 
then at day 10 of each cycle (= 5 assessments).
#Hospital Anxiety & Depression Scale (Zigmond & Snaith, 1983). This is a 14-item scale assessing anxiety 
with 7 items and depression with a further 7 items. Each item is answered on a 4-point scale (0–3). Scores 
on each sub-scale thus range between 0 (no symptoms) and 21 (numerous and severe symptoms). In this 
study, data will be obtained at baseline, the score of which will be used as a covariate in the final statistical 
analysis of the data, as anxiety and depression are key risk factors for the development of nausea/vomiting 
(Molassiotis et al, 2002b; Andrykowski et al, 1992). This scale has been used extensively with cancer 
patients as a screening tool and has been reported to have excellent psychometric properties. Completion 
time is approximately 2–5 min.
#Patient Expectations of Nausea/Vomiting. As this is a key risk factor identified in the literature (Molassiotis 
et al, 2002b; Andrykowski et al, 1992), as 2-item scale will be developed assessing the patient expectation 
for nausea and vomiting, measured on a 10-point ordinal scale. This will be incorporated in the final 
analysis of outcomes. Patients will also be asked how much they believe this method will help them 
alleviate nausea and how much faith they have in complementary therapies using 10-point scales. At the 
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end of each cycle, all patients will be asked to rate their overall tolerance of the chemotherapy on a 4-point 
scale, from ‘very well’ to ‘very poorly’ and record the reason for their choice.
#Measure of blindness of study. Patients in the intervention and sham arms of the study will be asked at 
the end of the study in which group they think they were allocated.
#Sociodemographic and treatment characteristics will be obtained from the patients’ records and the 
patients themselves. These will include gender, age, educational level, marital status, experience with 
nausea in the past such as during pregnancy, motion sickness or nausea when eating certain foods, use 
of/experience with other complementary therapies to manage nausea in the past, cancer diagnosis, stage 
of disease, and chemotherapy protocol used and dosage. Such a questionnaire is already developed by 
the team and used in the past in other nausea/vomiting studies. Medication use (standard and rescue 
antiemetics) during study participation will also be obtained from the pharmacy records.
Drop out cases will be asked to complete the Rhodes nausea experience 4-item subscale and failing this 
to answer a single item from the FACT scale about their nausea level. Scales will be given to patients to 
complete at home and return them back to researchers using a pre-paid envelope. Patients will be asked 
to complete their daily assessments of nausea at the same time in the evening to have a consistent time 
frame for measuring change. Patients who do not send back the completed scales within 2–3 days from 
the time they are suppose to return them will receive a reminder letter.
Measurement of costs
Costs will be identified, measured and valued using a micro-costing approach (by which each component 
of resource use is identified, estimated and a unit cost derived from market prices and national estimates 
(Curtis and Netten, 2006). The cost analysis will be performed from the perspective of the health service 
provider and from a societal perspective. Included in the health care provider costs will be those accrued by 
the acute trusts and PCTs. Costs to the patients and their families, including social care, will be considered 
as the additional costs for society. Indirect costs in terms of workdays lost will also be included.
Data will be collected prospectively and retrospectively using multiple sources including patient records and 
patient self reported questionnaires. The questionnaires will report health service utilisation subsequent to 
and as a result of chemotherapy induced nausea/vomiting (e.g. GP visits), patient out of pocket expenses 
such as over the counter medicines or transport together with use of services in the social sector such as 
home help and support from family and friends. Valuation of resource items including hospital resources 
(e.g. bed days and staff time) and community resources (e.g. GP visits, home help) use will be carried out 
using national estimates (Curtis and Netten, 2006); market prices will be assigned to medication; non-
market items, specifically patient time and informal help provided by family and friends, will be valued 
using market wage rates; out of pocket expenses (e.g. bus fares) will use financial expenditures.
In more detail, direct medical costs will be defined as those of prophylactic or rescue antiemetic 
medications, drug administration devices, staff time associated with preparing and administering 
medication and tending to patients with CINV, hospitalizations due to CINV, hospital outpatient or GP visits 
due to CINV and costs for over-the-counter medications or other complementary therapies. Direct non-
medical costs will be those for transportation and need for assistance, such as additional childcare. Indirect 
costs will be based exclusively on the number of workdays lost due to CINV. Costs that will not be included 
in this evaluation will be costs for chemotherapy agents, preplanned visits or hospitalizations for the 
purpose of chemotherapy administration, diagnostic and laboratory tests, and other patient management 
costs not directly related to CINV.
Analysis of Economic Data: The total cost of each arm of the trial will be calculated by combining the 
resource use and unit cost data. No discounting is necessary given the time period of data collection (less 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Molassiotis et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17260 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 26
111
than 1 year); sensitivity analysis will be carried out to account for uncertainty where estimates in cost 
data are used. Differences in costs between the three arms will be tested for using independent sample 
t-tests. Cost data in each of the arms will be analysed alongside the quality-of-life measures with the data 
combined and analysed using cost effectiveness ratios (i.e. the difference in costs between alternatives 
relative to the difference in effectiveness between the same alternatives). Cost per quality adjusted life year 
(QALY) will be presented.
Table of assessments:
Baseline 
assessment
Chemo days 
–1,0,1,2,3,4,5,6 × 4 
cycles
Chemo day 
10 × 4 cycles
End of study 
participation
Rhodes Index of NV 7
MAT 7
FACT-G 7 7
HADS 7 7
Patient Expectations Qr 7
Sociodemographic variables 7
Blindness assessment 7
Disease/treatment variables 7 7
Health economics assessment 7 7 7 7
Service user involvement
Service users will be involved at 3 levels. The first has been at the development phase of this proposal, 
with the contribution of the Chair of the NCRI Consumer Liaison group, who is a named co-applicant in 
the study, and reviews by expert patients. The second level will be monitoring the trial project and guiding 
it within its scientific framework through chairing and participating in the trial’s Steering committee and 
the DMEC. Finally, users will advise us in planning appropriate patient-focused dissemination of the trial 
results at the end of the study. For reviews, contacts, active involvement and access, the research partners’ 
strategy and mechanisms through the NCRI Cancer Experiences Collaborative will be utilised.
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